<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5f3a03d8-3583-4214-baa9-4fe16d2628d2"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Label"/>
   <title>These highlights do not include all the information needed to use SIROLIMUS ORAL SOLUTION safely and effectively. See full prescribing information for SIROLIMUS ORAL SOLUTION.<br/> SIROLIMUS oral solution <br/>  Initial U.S. Approval: 1999<br/>
   </title>
   <effectiveTime value="20250321"/>
   <setId root="580c1ec1-c1f5-45f6-89b7-3be25c07a0e5"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="081109687"/>
            <name>Novadoz Pharmaceuticals LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="079229051" root="1.3.6.1.4.1.519.1"/>
                        <name>MSN Pharmaceuticals Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72205-099" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72205-099" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="478259f2-5bbf-4d7c-92e2-5fd493ba0cbb"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20231205"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72205-099" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>sirolimus<suffix/>
                        </name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>sirolimus</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="1" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="W36ZG6FT64" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SIROLIMUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="W36ZG6FT64" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SIROLIMUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1T6N4D9YV6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SOYBEAN PHOSPHATIDYLCHOLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="HS7EB0C1ZH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUNFLOWER OIL MONO/DIGLYCERIDES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="HBA528N3PW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SOY ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QN83US2B0N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ASCORBYL PALMITATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R0ZB2556P8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TOCOPHEROL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43172" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="72205-099-78" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230214"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216728" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230119"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW">
                              <originalText>yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="rcm">
               <id root="35bd3516-31b6-4d9a-85b3-e446ff8980d3"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20231205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Warnings and Precautions, Cannabidiol Drug Interactions (<linkHtml href="#Section_5.21">5.21</linkHtml>)                 8/2022</paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_0">
               <id root="34dc9a9d-65a1-4744-8c26-2a9389c1e826"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG TRANSPLANT PATIENTS</title>
               <text>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Increased     susceptibility to infection and the possible development of lymphoma and other malignancies may result from     immunosuppression</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use sirolimus  for prophylaxis of organ rejection in patients receiving renal transplants. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [<content styleCode="italics">see <linkHtml href="#Section_5.1">Warnings and Precautions (5.1</linkHtml>)</content>]</content>.</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">The safety and     efficacy of sirolimus  as     immunosuppressive therapy have not been established in liver or lung transplant     patients, and therefore, such use is not recommended [<content styleCode="italics">see Warnings and     Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>,<linkHtml href="#Section_5.3">5.3</linkHtml>)</content>]</content>.</item>
                     <item>
                        <content styleCode="bold">Liver Transplantation – Excess Mortality, Graft Loss, and Hepatic Artery Thrombosis (HAT)</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">The use of sirolimus  in combination with tacrolimus was associated with excess mortality and graft loss in a study in <content styleCode="italics">de novo </content>liver transplant patients. Many of these patients had evidence of infection at or near the time of death.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">In this and another study in <content styleCode="italics">de novo </content>liver transplant patients, the use of sirolimus  in combination with cyclosporine or tacrolimus was associated with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation and most led to graft loss or death [<content styleCode="italics">see <linkHtml href="#Section_5.2">Warnings and Precautions (5.2</linkHtml>)</content>].</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Lung     Transplantation – Bronchial Anastomotic Dehiscence</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Cases of bronchial anastomotic dehiscence, most fatal, have been reported in de novo lung transplant patients when sirolimus  has been used as part of an immunosuppressive regimen [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)</content>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20231205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG TRANSPLANT PATIENTS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Increased     susceptibility to infection and the possible development of lymphoma and other     malignancies may result from immunosuppression (<linkHtml href="#Section_5.1">5.1</linkHtml>). Only physicians     experienced in immunosuppressive therapy and management of renal transplant     patients should use sirolimus for prophylaxis of organ rejection in patients     receiving renal transplants.</content>
                           </item>
                           <item>
                              <content styleCode="bold">The safety and     efficacy of sirolimus as immunosuppressive therapy have not been established in     liver or lung transplant patients, and therefore, such use is not recommended     (<linkHtml href="#Section_5.2">5.2</linkHtml>
                                 <content styleCode="italics">, </content>
                                 <linkHtml href="#Section_5.3">5.3</linkHtml>).</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">– Liver Transplantation – Excess mortality, graft loss, and hepatic artery thrombosis (<linkHtml href="#Section_5.2">5.2</linkHtml>).<br/> – Lung Transplantation – Bronchial anastomotic dehiscence (<linkHtml href="#Section_5.3">5.3</linkHtml>).</content>
                        </paragraph>
                        <br/>
                        <paragraph>  </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="e4d42f0c-fabd-472c-9ebb-d25eab0d07d7"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20231205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Sirolimus oral solution is     an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ     rejection in patients aged ≥13 years receiving renal transplants:<list listType="unordered" styleCode="Circle">
                                 <item>Patients at low- to moderate-immunologic risk: Use         initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is         recommended 2-4 months after transplantation (<linkHtml href="#Section_1.1">1.1</linkHtml>).</item>
                                 <item>Patients at high-immunologic risk: Use in         combination with CsA and corticosteroids for the first 12 months following         transplantation (<linkHtml href="#Section_1.1">1.1</linkHtml>). Safety and efficacy of CsA withdrawal has not been established in high risk patients (<linkHtml href="#Section_1.1">1.1</linkHtml>,<linkHtml href="#Section_1.2">1.2</linkHtml>,<linkHtml href="#Section_14.3">14.3</linkHtml>).</item>
                              </list>
                           </item>
                        </list>
                        <list listType="unordered" styleCode="disc">
                           <item> Sirolimus  oral solution is an mTOR inhibitor indicated     for the treatment of patients with lymphangioleiomyomatosis (<linkHtml href="#Section_1.3">1.3</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_1.1">
                     <id root="352d6a81-ee17-404f-8819-96263be2b897"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.1 Prophylaxis of Organ Rejection in Renal Transplantation</title>
                     <text>
                        <paragraph>Sirolimus oral solution is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants.</paragraph>
                        <paragraph>
                           <content styleCode="underline">In patients at low-to moderate-immunologic risk</content>
                           <content styleCode="bold">, </content>it is recommended that sirolimus oral solution be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">In patients at high-immunologic risk </content>(defined as Black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [PRA; peak PRA level &gt;80%]), it is recommended that sirolimus oral solution be used in combination with cyclosporine and corticosteroids for the first year following transplantation [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.3">2.3</linkHtml>)</content>, <content styleCode="italics">Clinical Studies (<linkHtml href="#Section_14.3">14.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.2">
                     <id root="c50a797e-df17-48fc-b53b-cd1540e99ca2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.2 Limitations of Use in Renal Transplantation</title>
                     <text>
                        <paragraph>Cyclosporine withdrawal has not been studied in patients with Banff Grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal, those who are dialysis-dependent, those with serum creatinine &gt;4.5 mg/dL, Black patients, patients of multi-organ transplants, secondary transplants, or those with high levels of panel-reactive antibodies [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.2">14.2</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">In patients at high-immunologic risk</content>
                           <content styleCode="bold">, </content>the safety and efficacy of sirolimus used in combination with cyclosporine and corticosteroids has not been studied beyond one year; therefore after the first 12 months following transplantation, any adjustments to the immunosuppressive regimen should be considered on the basis of the clinical status of the patient [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.3">14.3</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">In pediatric patients</content>, the safety and efficacy of sirolimus have not been established in patients &lt;13 years old, or in pediatric (&lt;18 years) renal transplant patients considered at high-immunologic risk [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.5">6.5</linkHtml>), Clinical Studies (<linkHtml href="#Section_14.6">14.6</linkHtml>)</content>].</paragraph>
                        <paragraph>The safety and efficacy of <content styleCode="italics">de novo </content>use of sirolimus without cyclosporine have not been established in renal transplant patients [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.12">5.12</linkHtml>)</content>].</paragraph>
                        <paragraph> The safety and efficacy of <content styleCode="underline">conversion from calcineurin inhibitors to sirolimus</content> in maintenance renal transplant patients have not been established [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.4">14.4</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.3">
                     <id root="1988049d-9557-4094-ad00-62d7723b11a4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.3 Treatment of Patients with Lymphangioleiomyomatosis</title>
                     <text>
                        <paragraph>Sirolimus oral solution is indicated for the treatment of patients with lymphangioleiomyomatosis (LAM).</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="87525b4f-a9bf-496e-a700-1e8601390db4"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Sirolimus oral solution is to be administered orally once daily, consistently with or without food [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.5">2.5</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>].</paragraph>
               </text>
               <effectiveTime value="20231205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Renal Transplant Patients:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <paragraph>Administer once daily by mouth, consistently with or without food (<linkHtml href="#Section_2">2</linkHtml>).</paragraph>
                           </item>
                           <item>
                              <paragraph>Administer the initial dose as soon as possible     after transplantation and 4 hours after CsA (<linkHtml href="#Section_2.1">2.1</linkHtml>,<linkHtml href="#Section_7.1">7.1</linkHtml>).</paragraph>
                           </item>
                           <item>
                              <paragraph>Adjust the sirolimus maintenance     dose to achieve sirolimus trough concentrations within the target-range (<linkHtml href="#Section_2.5">2.5</linkHtml>).</paragraph>
                           </item>
                           <item>
                              <paragraph>Hepatic impairment: Reduce maintenance dose in     patients with hepatic impairment (<linkHtml href="#Section_2.7">2.7</linkHtml>, <linkHtml href="#Section_8.8">8.6</linkHtml>,<linkHtml href="#Section_12.3">12.3</linkHtml>).</paragraph>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">In renal transplant patients at low-to moderate-immunologic risk</content>:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <paragraph>Sirolimus oral solution and     CsA Combination Therapy: One loading dose of 6 mg on day 1, followed by daily     maintenance doses of 2 mg (<linkHtml href="#Section_2.2">2.2</linkHtml>).</paragraph>
                           </item>
                           <item>
                              <paragraph>Sirolimus oral solution Following CsA     Withdrawal: 2-4 months post-transplantation, withdraw CsA over 4-8 weeks (<linkHtml href="#Section_2.2">2.2</linkHtml>).</paragraph>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">In renal transplant patients at high-immunologic risk:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <paragraph>Sirolimus oral solution and     CsA Combination Therapy (for the first 12 months post-transplantation): One loading     dose of up to 15 mg on day 1, followed by daily maintenance doses of 5 mg (<linkHtml href="#Section_2.3">2.3</linkHtml>).</paragraph>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Lymphangioleiomyomatosis Patients:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <paragraph>Administer once daily by mouth, consistently with or without food (<linkHtml href="#Section_2">2</linkHtml>).</paragraph>
                           </item>
                           <item>
                              <paragraph>Recommended initial sirolimus     oral solution dose is 2 mg/day (<linkHtml href="#Section_2.4">2.4</linkHtml>).</paragraph>
                           </item>
                           <item>
                              <paragraph>Adjust the sirolimus     oral solution dose to achieve sirolimus trough concentrations between 5-15 ng/mL (<linkHtml href="#Section_2.4">2.4</linkHtml>).</paragraph>
                           </item>
                           <item>
                              <paragraph>Hepatic impairment: Reduce maintenance dose in     patients with hepatic impairment (<linkHtml href="#Section_2.7">2.7</linkHtml>, <linkHtml href="#Section_8.8">8.6</linkHtml>,<linkHtml href="#Section_12.3">12.3</linkHtml>).</paragraph>
                           </item>
                        </list>
                        <paragraph> Therapeutic drug monitoring is recommended for all patients (<linkHtml href="#Section_2.5">2.5</linkHtml>, <linkHtml href="#Section_5.17">5.17</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="84d2465d-b66b-4ae0-aafa-3e7d356f8697"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.1 General Dosing Guidance for Renal Transplant Patients</title>
                     <text>
                        <paragraph>The initial dose of sirolimus oral solution should be administered as soon as possible after transplantation. It is recommended that sirolimus be taken 4 hours after administration of cyclosporine oral solution (MODIFIED) and or/cyclosporine capsules (MODIFIED) [<content styleCode="italics">see Drug Interactions (<linkHtml href="#Section_7.2">7.2</linkHtml>)</content>].</paragraph>
                        <paragraph>Frequent sirolimus oral solution dose adjustments based on non-steady-state sirolimus concentrations can lead to overdosing or underdosing because sirolimus has a long half-life. Once sirolimus maintenance dose is adjusted, patients should continue on the new maintenance dose for at least 7 to 14 days before further dosage adjustment with concentration monitoring. In most patients, dose adjustments can be based on simple proportion: new sirolimus oral solution dose = current dose x (target concentration/current concentration). A loading dose should be considered in addition to a new maintenance dose when it is necessary to increase sirolimus trough concentrations: sirolimus oral solution loading dose = 3 x (new maintenance dose - current maintenance dose). The maximum sirolimus oral solution dose administered on any day should not exceed 40 mg. If an estimated daily dose exceeds 40 mg due to the addition of a loading dose, the loading dose should be administered over 2 days. Sirolimus trough concentrations should be monitored at least 3 to 4 days after a loading dose(s).</paragraph>
                        <paragraph> Two milligrams (2 mg) of sirolimus oral solution have been demonstrated to be clinically equivalent to 2 mg sirolimus tablets; hence, at this dose these two formulations are interchangeable. However, it is not known if higher doses of sirolimus oral solution are clinically equivalent to higher doses of sirolimus tablets on a mg-to-mg basis [<content styleCode="italics">see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="e3d6d6b2-acc1-4a46-b19b-bf7447bcf74f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.2 Renal Transplant Patients at Low- to Moderate-Immunologic Risk</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Sirolimus and Cyclosporine Combination Therapy</content>
                        </paragraph>
                        <paragraph>For <content styleCode="italics">de novo </content>renal transplant patients, it is recommended that sirolimus oral solution be used initially in a regimen with cyclosporine and corticosteroids. A loading dose of sirolimus equivalent to 3 times the maintenance dose should be given, i.e. a daily maintenance dose of 2 mg should be preceded with a loading dose of 6 mg. Therapeutic drug monitoring should be used to maintain sirolimus drug concentrations within the target-range [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.5">2.5</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Sirolimus</content>
                           <content styleCode="underline"> Following Cyclosporine Withdrawal</content>
                        </paragraph>
                        <paragraph> At 2 to 4 months following transplantation, cyclosporine should be progressively discontinued over 4 to 8 weeks, and the sirolimus dose should be adjusted to obtain sirolimus whole blood trough concentrations within the target-range [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.5">2.5</linkHtml>)</content>]. Because cyclosporine inhibits the metabolism and transport of sirolimus, sirolimus concentrations may decrease when cyclosporine is discontinued, unless the sirolimus dose is increased [<content styleCode="italics">see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="9bef9a9e-f492-4ab9-afd1-4da046a1d88a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.3 Renal Transplant Patients at High-Immunologic Risk</title>
                     <text>
                        <paragraph>In patients with high-immunologic risk, it is recommended that sirolimus oral solution be used in combination with cyclosporine and corticosteroids for the first 12 months following transplantation [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.3">14.3</linkHtml>)</content>]. The safety and efficacy of this combination in high-immunologic risk patients has not been studied beyond the first 12 months. Therefore, after the first 12 months following transplantation, any adjustments to the immunosuppressive regimen should be considered on the basis of the clinical status of the patient.</paragraph>
                        <paragraph>For patients receiving sirolimus with cyclosporine, sirolimus therapy should be initiated with a loading dose of up to 15 mg on day 1 post-transplantation. Beginning on day 2, an initial maintenance dose of 5 mg/day should be given. A trough level should be obtained between days 5 and 7, and the daily dose of sirolimus should thereafter be adjusted [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.5">2.5</linkHtml>)</content>].</paragraph>
                        <paragraph>The starting dose of cyclosporine should be up to 7 mg/kg/day in divided doses and the dose should subsequently be adjusted to achieve target whole blood trough concentrations [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.5">2.5</linkHtml>)</content>]. Prednisone should be administered at a minimum of 5 mg/day.</paragraph>
                        <paragraph> Antibody induction therapy may be used.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.4">
                     <id root="1f96d3b8-f043-4ad1-87d6-1e7c0bbe6641"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.4 Dosing in Patients with Lymphangioleiomyomatosis</title>
                     <text>
                        <paragraph>For patients with lymphangioleiomyomatosis, the initial sirolimus oral solution dose should be 2 mg/day. Sirolimus whole blood trough concentrations should be measured in 10-20 days, with dosage adjustment to maintain concentrations between 5-15 ng/mL [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.5">2.5</linkHtml>)</content>].</paragraph>
                        <paragraph> In most patients, dose adjustments can be based on simple proportion: new sirolimus oral solution dose = current dose x (target concentration/current concentration). Frequent sirolimus oral solution dose adjustments based on non-steady-state sirolimus concentrations can lead to overdosing or under dosing because sirolimus has a long half-life. Once sirolimus oral solution maintenance dose is adjusted, patients should continue on the new maintenance dose for at least 7 to 14 days before further dosage adjustment with concentration monitoring. Once a stable dose is achieved, therapeutic drug monitoring should be performed at least every three months.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.5">
                     <id root="d80e5385-5246-465f-9cab-33d6d0474535"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.5 Therapeutic Drug Monitoring</title>
                     <text>
                        <paragraph>Monitoring of sirolimus trough concentrations is recommended for all patients, especially in those patients likely to have altered drug metabolism, in patients ≥ 13 years who weigh less than 40 kg, in patients with hepatic impairment, when a change in the sirolimus dosage form is made, and during concurrent administration of strong CYP3A4 inducers and inhibitors <content styleCode="italics">[<linkHtml href="#Section_5.20">see Warnings and Precautions (5.20</linkHtml>, <linkHtml href="#Section_5.21">5.21</linkHtml>), <linkHtml href="#Section_7">Drug Interactions (7)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Therapeutic drug monitoring should not be the sole basis for adjusting sirolimus therapy. Careful attention should be made to clinical signs/symptoms, tissue biopsy findings, and laboratory parameters.</paragraph>
                        <paragraph>When used in combination with cyclosporine, sirolimus trough concentrations should be maintained within the target-range [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14">14</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>]. Following cyclosporine withdrawal in transplant patients at low- to moderate-immunologic risk, the target sirolimus trough concentrations should be 16 to 24 ng/mL for the first year following transplantation. Thereafter, the target sirolimus concentrations should be 12 to 20 ng/mL.</paragraph>
                        <paragraph>The above recommended 24-hour trough concentration ranges for sirolimus are based on chromatographic methods. Currently in clinical practice, sirolimus whole blood concentrations are being measured by both chromatographic and immunoassay methodologies. Because the measured sirolimus whole blood concentrations depend on the type of assay used, the concentrations obtained by these different methodologies are not interchangeable [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.17">5.17</linkHtml>)</content>, <content styleCode="italics">Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>]. Adjustments to the targeted range should be made according to the assay utilized to determine sirolimus trough concentrations. Since results are assay and laboratory dependent, and the results may change over time, adjustments to the targeted therapeutic range must be made with a detailed knowledge of the site-specific assay used. Therefore, communication should be maintained with the laboratory performing the assay. A discussion of different assay methods is contained in Clinical Therapeutics, Volume 22, Supplement B, April 2000 [<content styleCode="italics">see References (<linkHtml href="#Section_15">15</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.6">
                     <id root="c914ac4c-dd6e-4f5c-aba2-14b44fb111f5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.6 Patients with Low Body Weight</title>
                     <text>
                        <paragraph>The initial dosage in patients ≥13 years who weigh less than 40 kg should be adjusted, based on body surface area, to 1 mg/m<sup>2</sup>/day. The loading dose should be 3 mg/m<sup>2</sup>.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.7">
                     <id root="67313ffc-7c7f-442b-94be-8bd26138f35e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.7 Patients with Hepatic Impairment</title>
                     <text>
                        <paragraph>It is recommended that the maintenance dose of sirolimus be reduced by approximately one third in patients with mild or moderate hepatic impairment and by approximately one half in patients with severe hepatic impairment. It is not necessary to modify the sirolimus loading dose [<content styleCode="italics">see Use in Specific Populations (<linkHtml href="#Section_8.8">8.6</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.8">
                     <id root="51cc3d09-8c7f-40cd-a8b9-43b6d1333c9e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.8 Patients with Renal Impairment</title>
                     <text>
                        <paragraph>Dosage adjustment is not needed in patients with impaired renal function [<content styleCode="italics">see Use in Specific Populations (<linkHtml href="#Section_8.9">8.7</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.9">
                     <id root="85e030e9-163a-45b5-8171-091461273371"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.9 Instructions for Dilution and Administration of Sirolimus Oral Solution</title>
                     <text>
                        <paragraph>The amber oral dose syringe should be used to withdraw the prescribed amount of sirolimus oral solution from the bottle. Empty the correct amount of sirolimus from the syringe into only a glass or plastic container holding at least two (2) ounces (1/4 cup, 60 mL) of water or orange juice. No other liquids, including grapefruit juice, should be used for dilution [<content styleCode="italics">see Drug Interactions (<linkHtml href="#Section_7.3">7.3</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>]. Stir vigorously and drink at once. Refill the container with an additional volume [minimum of four (4) ounces (1/2 cup, 120 mL)] of water or orange juice, stir vigorously, and drink at once.</paragraph>
                        <paragraph> Sirolimus oral solution contains polysorbate 80, which is known to increase the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC). This should be considered during the preparation and administration of sirolimus oral solution. It is important that these recommendations be followed closely.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="feae726b-41be-4be2-8752-e4d28f014afc"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <effectiveTime value="20231205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>•  Oral Solution: 60 mg per 60 mL in amber glass bottle (<linkHtml href="#Section_3.1">3.1</linkHtml>).</paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_3.1">
                     <id root="b81011a5-c6bd-4af8-b6bf-d7ddc0f7938d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>3.1 Sirolimus Oral Solution</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>60 mg per 60 mL in     amber glass bottle.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="b5e35c13-fe03-48a6-b54b-9e9bb92ed235"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Sirolimus is contraindicated in patients with a hypersensitivity to sirolimus [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)</content>].</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20231205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>•  Hypersensitivity to sirolimus (<linkHtml href="#Section_4">4</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="7f2e5e6d-76e7-463b-9986-246908978a14"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20231205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <paragraph>Hypersensitivity Reactions (<linkHtml href="#Section_5.4">5.4</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Angioedema (<linkHtml href="#Section_5.5">5.5</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Fluid Accumulation and Impairment of Wound Healing     (<linkHtml href="#Section_5.6">5.6</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Hyperlipidemia (<linkHtml href="#Section_5.7">5.7</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Decline in Renal Function (<linkHtml href="#Section_5.8">5.8</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Proteinuria (<linkHtml href="#Section_5.9">5.9</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Latent Viral Infections (<linkHtml href="#Section_5.10">5.10</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Interstitial Lung Disease/Non-Infectious Pneumonitis     (<linkHtml href="#Section_5.11">5.11</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>
                                 <content styleCode="italics">De Novo </content>Use Without Cyclosporine <linkHtml href="#Section_5.12">(5.12</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Increased Risk of Calcineurin Inhibitor-Induced     Hemolytic Uremic Syndrome/ Thrombotic Thrombocytopenic Purpura/ Thrombotic     Microangiopathy (<linkHtml href="#Section_5.13">5.13</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Embryo-Fetal Toxicity: Can cause fetal harm. Use of     highly effective contraception is recommended for females of reproductive     potential during treatment and for 12 weeks after final dose of sirolimus (<linkHtml href="#Section_5.15">5.15</linkHtml>, <linkHtml href="#Section_8.1">8.1</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Male Infertility: Azoospermia or oligospermia may     occur (<linkHtml href="#Section_5.16">5.16</linkHtml>, <linkHtml href="#Section_13.1">13.1</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Immunizations: Avoid live vaccines (<linkHtml href="#Section_5.19">5.19</linkHtml>)</paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="ce3a1abe-7d0e-4170-939a-ccebb0eb098a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.1 Increased Susceptibility to Infection and the Possible Development of Lymphoma</title>
                     <text>
                        <paragraph>Increased susceptibility to infection and the possible development of lymphoma and other malignancies, particularly of the skin, may result from immunosuppression. The rates of lymphoma/lymphoproliferative disease observed in Studies 1 and 2 were 0.7-3.2% (for sirolimus-treated patients) versus 0.6-0.8% (azathioprine and placebo control) [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>) </content>and <content styleCode="italics">(<linkHtml href="#Section_6.2">6.2</linkHtml>)</content>]. Oversuppression of the immune system can also increase susceptibility to infection, including opportunistic infections such as tuberculosis, fatal infections, and sepsis. Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should use sirolimus for prophylaxis of organ rejection in patients receiving renal transplants. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="5d7701de-b2f5-4435-8329-5795eaecefad"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.2 Liver Transplantation – Excess Mortality, Graft Loss, and Hepatic Artery Thrombosis</title>
                     <text>
                        <paragraph>The safety and efficacy of sirolimus as immunosuppressive therapy have not been established in liver transplant patients; therefore, such use is not recommended. The use of sirolimus has been associated with adverse outcomes in patients following liver transplantation, including excess mortality, graft loss and hepatic artery thrombosis (HAT).</paragraph>
                        <paragraph>In a study in <content styleCode="italics">de novo </content>liver transplant patients, the use of sirolimus in combination with tacrolimus was associated with excess mortality and graft loss (22% in combination versus 9% on tacrolimus alone). Many of these patients had evidence of infection at or near the time of death.</paragraph>
                        <paragraph>In this and another study in <content styleCode="italics">de novo </content>liver transplant patients, the use of sirolimus in combination with cyclosporine or tacrolimus was associated with an increase in HAT (7% in combination versus 2% in the control arm); most cases of HAT occurred within 30 days post-transplantation, and most led to graft loss or death.</paragraph>
                        <paragraph> In a clinical study in stable liver transplant patients 6-144 months post-liver transplantation and receiving a CNI-based regimen, an increased number of deaths was observed in the group converted to a sirolimus-based regimen compared to the group who was continued on a CNI-based regimen, although the difference was not statistically significant (3.8% versus 1.4%) [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.5">14.5</linkHtml>)</content>].</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="7623adaf-2edb-41d6-a51f-af88dc7f3832"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.3 Lung Transplantation – Bronchial Anastomotic Dehiscence</title>
                     <text>
                        <paragraph>Cases of bronchial anastomotic dehiscence, most fatal, have been reported in <content styleCode="italics">de novo </content>lung transplant patients when sirolimus has been used as part of an immunosuppressive regimen.</paragraph>
                        <paragraph> The safety and efficacy of sirolimus as immunosuppressive therapy have not been established in lung transplant patients; therefore, such use is not recommended.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="e0cb8099-945a-4898-9cf1-6060da02477a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.4 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, angioedema, exfoliative dermatitis and hypersensitivity vasculitis, have been associated with the administration of sirolimus [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.7">6.7</linkHtml>)</content>].</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="77aeee4c-5cbc-45f9-a6ae-02a30fdbc82b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.5 Angioedema</title>
                     <text>
                        <paragraph>Sirolimus has been associated with the development of angioedema. The concomitant use of sirolimus with other drugs known to cause angioedema, such as angiotensin-converting enzyme (ACE) inhibitors, may increase the risk of developing angioedema. Elevated sirolimus levels (with/without concomitant ACE inhibitors) may also potentiate angioedema [<content styleCode="italics">see Drug Interactions (<linkHtml href="#Section_7.2">7.2</linkHtml>)</content>]. In some cases, the angioedema has resolved upon discontinuation or dose reduction of sirolimus.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="27825d70-9061-4dd4-96c2-e65e514274e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.6 Fluid Accumulation and Impairment of Wound Healing</title>
                     <text>
                        <paragraph>There have been reports of impaired or delayed wound healing in patients receiving sirolimus, including lymphocele and wound dehiscence [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)</content>]. Mammalian target of rapamycin (mTOR) inhibitors such as sirolimus have been shown <content styleCode="italics">in vitro </content>to inhibit production of certain growth factors that may affect angiogenesis, fibroblast proliferation, and vascular permeability. Lymphocele, a known surgical complication of renal transplantation, occurred significantly more often in a dose-related fashion in patients treated with sirolimus [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)</content>]. Appropriate measures should be considered to minimize such complications. Patients with a body mass index (BMI) greater than 30 kg/m<sup>2</sup> may be at increased risk of abnormal wound healing based on data from the medical literature.</paragraph>
                        <paragraph> There have also been reports of fluid accumulation, including peripheral edema, lymphedema, pleural effusion, ascites, and pericardial effusions (including hemodynamically significant effusions and tamponade requiring intervention in children and adults), in patients receiving sirolimus.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.7">
                     <id root="fd358131-5927-4c8b-aaa1-b7952dc926e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.7 Hyperlipidemia</title>
                     <text>
                        <paragraph>Increased serum cholesterol and triglycerides requiring treatment occurred more frequently in patients treated with sirolimus compared with azathioprine or placebo controls in Studies 1 and 2 [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)</content>]. There were increased incidences of hypercholesterolemia (43-46%) and/or hypertriglyceridemia (45- 57%) in patients receiving sirolimus compared with placebo controls (each 23%). The risk/benefit should be carefully considered in patients with established hyperlipidemia before initiating an immunosuppressive regimen including sirolimus.</paragraph>
                        <paragraph>Any patient who is administered sirolimus should be monitored for hyperlipidemia. If detected, interventions such as diet, exercise, and lipid-lowering agents should be initiated as outlined by the National Cholesterol Education Program guidelines.</paragraph>
                        <paragraph>In clinical trials of patients receiving sirolimus plus cyclosporine or sirolimus after cyclosporine withdrawal, up to 90% of patients required treatment for hyperlipidemia and hypercholesterolemia with anti-lipid therapy (e.g., statins, fibrates). Despite anti-lipid management, up to 50% of patients had fasting serum cholesterol levels &gt;240 mg/dL and triglycerides above recommended target levels. The concomitant administration of sirolimus and HMG-CoA reductase inhibitors resulted in adverse reactions such as CPK elevations (3%), myalgia (6.7%) and rhabdomyolysis (&lt;1%). In these trials, the number of patients was too small and duration of follow-up too short to evaluate the long-term impact of sirolimus on cardiovascular mortality.</paragraph>
                        <paragraph> During sirolimus therapy with or without cyclosporine, patients should be monitored for elevated lipids, and patients administered an HMG-CoA reductase inhibitor and/or fibrate should be monitored for the possible development of rhabdomyolysis and other adverse effects, as described in the respective labeling for these agents.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.8">
                     <id root="9071bfd7-4157-424b-8b97-41ded42130b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.8 Decline in Renal Function</title>
                     <text>
                        <paragraph>Renal function should be closely monitored during the co-administration of sirolimus with cyclosporine, because long-term administration of the combination has been associated with deterioration of renal function. Patients treated with cyclosporine and sirolimus were noted to have higher serum creatinine levels and lower glomerular filtration rates compared with patients treated with cyclosporine and placebo or azathioprine controls (Studies 1 and 2). The rate of decline in renal function in these studies was greater in patients receiving sirolimus and cyclosporine compared with control therapies.</paragraph>
                        <paragraph>Appropriate adjustment of the immunosuppressive regimen, including discontinuation of sirolimus and/or cyclosporine, should be considered in patients with elevated or increasing serum creatinine levels. In patients at low- to moderate-immunologic risk, continuation of combination therapy with cyclosporine beyond 4 months following transplantation should only be considered when the benefits outweigh the risks of this combination for the individual patients. Caution should be exercised when using agents (e.g., aminoglycosides and amphotericin B) that are known to have a deleterious effect on renal function.</paragraph>
                        <paragraph> In patients with delayed graft function, sirolimus may delay recovery of renal function.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.9">
                     <id root="6a9ed3df-94b8-4b36-8b14-ccd5add3c88a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.9 Proteinuria</title>
                     <text>
                        <paragraph>Periodic quantitative monitoring of urinary protein excretion is recommended. In a study evaluating conversion from calcineurin inhibitors (CNI) to sirolimus in maintenance renal transplant patients 6-120 months post- transplant, increased urinary protein excretion was commonly observed from 6 through 24 months after conversion to sirolimus compared with CNI continuation [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.4">14.4</linkHtml>), Adverse Reactions (<linkHtml href="#Section_6.4">6.4</linkHtml>)</content>]. Patients with the greatest amount of urinary protein excretion prior to sirolimus conversion were those whose protein excretion increased the most after conversion. New onset nephrosis (nephrotic syndrome) was also reported as a treatment-emergent adverse reaction in 2.2% of the sirolimus conversion group patients in comparison to 0.4% in the CNI continuation group of patients. Nephrotic range proteinuria (defined as urinary protein to creatinine ratio &gt;3.5) was also reported in 9.2% in the sirolimus conversion group of patients in comparison to 3.7% in the CNI continuation group of patients. In some patients, reduction in the degree of urinary protein excretion was observed for individual patients following discontinuation of sirolimus. The safety and efficacy of conversion from calcineurin inhibitors to sirolimus in maintenance renal transplant patients have not been established.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.10">
                     <id root="ffd416d6-3a7c-4d89-b261-0bfe53d6af50"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.10 Latent Viral Infections</title>
                     <text>
                        <paragraph>Immunosuppressed patients are at increased risk for opportunistic infections, including activation of latent viral infections. These include BK virus-associated nephropathy, which has been observed in renal transplant patients receiving immunosuppressants, including sirolimus. This infection may be associated with serious outcomes, including deteriorating renal function and renal graft loss [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.7">6.7</linkHtml>)</content>]. Patient monitoring may help detect patients at risk for BK virus-associated nephropathy. Reduction in immunosuppression should be considered for patients who develop evidence of BK virus-associated nephropathy.</paragraph>
                        <paragraph> Cases of progressive multifocal leukoencephalopathy (PML), sometimes fatal have been reported in patients treated with immunosuppressants, including sirolimus. PML commonly presents with hemiparesis, apathy, confusion, cognitive deficiencies and ataxia. Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function. In immunosuppressed patients, physicians should consider PML in the differential diagnosis in patients reporting neurological symptoms and consultation with a neurologist should be considered as clinically indicated. Consideration should be given to reducing the amount of immunosuppression in patients who develop PML. In transplant patients, physicians should also consider the risk that reduced immunosuppression represents to the graft.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.11">
                     <id root="8af5f904-c64f-4eb6-acb2-2e13b792718b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.11 Interstitial Lung Disease/Non-Infectious Pneumonitis</title>
                     <text>
                        <paragraph>Cases of interstitial lung disease [ILD] (including pneumonitis, bronchiolitis obliterans organizing pneumonia [BOOP], and pulmonary fibrosis), some fatal, with no identified infectious etiology have occurred in patients receiving immunosuppressive regimens including sirolimus. In some cases, the ILD was reported with pulmonary hypertension (including pulmonary arterial hypertension [PAH]) as a secondary event. In some cases, the ILD has resolved upon discontinuation or dose reduction of sirolimus. The risk may be increased as the trough sirolimus concentration increases [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.7">6.7</linkHtml>)</content>].</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.12">
                     <id root="4780f683-97d9-406d-9f9f-5834e2d38159"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.12 <content styleCode="italics">De Novo</content> Use Without Cyclosporine</title>
                     <text>
                        <paragraph>The safety and efficacy of <content styleCode="italics">de novo </content>use of sirolimus without cyclosporine is not established in renal transplant patients. In a multicenter clinical study, <content styleCode="italics">de novo </content>renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. A benefit, in terms of better renal function, was not apparent in the treatment arm with <content styleCode="italics">de novo </content>use of sirolimus without cyclosporine. These findings were also observed in a similar treatment group of another clinical trial.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.13">
                     <id root="a4dca76e-0931-4d0f-8c07-30e581754525"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.13 Increased Risk of Calcineurin Inhibitor-Induced Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura/Thrombotic Microangiopathy</title>
                     <text>
                        <paragraph>The concomitant use of sirolimus with a calcineurin inhibitor may increase the risk of calcineurin inhibitor- induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.7">6.7</linkHtml>)</content>].</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.14">
                     <id root="0609df9b-454e-4a52-ad85-24ba8f18bf3e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.14 Antimicrobial Prophylaxis</title>
                     <text>
                        <paragraph>Cases of <content styleCode="italics">Pneumocystis carinii </content>pneumonia have been reported in transplant patients not receiving antimicrobial prophylaxis. Therefore, antimicrobial prophylaxis for <content styleCode="italics">Pneumocystis carinii </content>pneumonia should be administered for 1 year following transplantation.</paragraph>
                        <paragraph> Cytomegalovirus (CMV) prophylaxis is recommended for 3 months after transplantation, particularly for patients at increased risk for CMV disease.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.15">
                     <id root="9fa5f4fe-96d4-43ad-ab90-24882634cac3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.15 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on animal studies and the mechanism of action [<content styleCode="italics">see Clinical Pharmacology (<linkHtml href="#Section_12.1">12.1</linkHtml>)</content>], sirolimus can cause fetal harm when administered to a pregnant woman. In animal studies, sirolimus caused embryo-fetal toxicity when administered during the period of organogenesis at maternal exposures that were equal to or less than human exposures at the recommended lowest starting dose. Advise pregnant women of the potential risk to a fetus. Advise female patients of reproductive potential to avoid becoming pregnant and to use highly effective contraception while using sirolimus and for 12 weeks after ending treatment [<content styleCode="italics">see Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.16">
                     <id root="359987cf-dbea-49dc-b667-6cc4bf58ffc3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.16 Male Infertility</title>
                     <text>
                        <paragraph>Azoospermia or oligospermia may be observed [<content styleCode="italics">
                              <linkHtml href="#Section_6.7">see Adverse Reactions (6.7)</linkHtml>, Nonclinical Toxicology (<linkHtml href="#Section_13.1">13.1</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>Sirolimus is an anti-proliferative drug and affects rapidly dividing cells like the germ cells.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.17">
                     <id root="bb2831ac-a9b2-425f-b9fc-aa75b0fd431a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.17 Different Sirolimus Trough Concentrations Reported between Chromatographic and Immunoassay Methodologies</title>
                     <text>
                        <paragraph>Currently in clinical practice, sirolimus whole blood concentrations are being measured by various chromatographic and immunoassay methodologies. Patient sample concentration values from different assays may not be interchangeable [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.5">2.5</linkHtml>)</content>].</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.18">
                     <id root="66f0a054-409f-454d-859b-133ed7eac2ce"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.18 Skin Cancer Events</title>
                     <text>
                        <paragraph>Patients on immunosuppressive therapy are at increased risk for skin cancer. Exposure to sunlight and ultraviolet (UV) light should be limited by wearing protective clothing and using a broad spectrum sunscreen with a high protection factor [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>, <linkHtml href="#Section_6.2">6.2</linkHtml>, <linkHtml href="#Section_6.7">6.7</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.19">
                     <id root="b8cbcba5-f1f9-431d-941b-e95310a8c0dd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.19 Immunizations</title>
                     <text>
                        <paragraph>The use of live vaccines should be avoided during treatment with sirolimus; live vaccines may include, but are not limited to, the following: measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid. Immunosuppressants may affect response to vaccination. Therefore, during treatment with sirolimus, vaccination may be less effective.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.20">
                     <id root="023ee9b4-7cca-47da-b28b-58186d460cfb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.20 Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp</title>
                     <text>
                        <paragraph>Avoid concomitant use of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) [<content styleCode="italics">see Drug Interactions (<linkHtml href="#Section_7.2">7.2</linkHtml>)</content>].</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.21">
                     <id root="1f5d642d-57c6-4668-b909-a52fa18cbba1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.21	Cannabidiol Drug Interactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">When cannabidiol and sirolimus are co-administered, closely monitor for an increase in sirolimus blood levels and for adverse reactions suggestive of sirolimus toxicity. A dose reduction of sirolimus should be considered as needed when sirolimus is co-administered with cannabidiol <content styleCode="italics">[<linkHtml href="#Section_2.5">see Dosage and Administration (2.5)</linkHtml> and <linkHtml href="#Section_7.5">Drug Interactions (7.5)</linkHtml>].</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="54bf896a-98c7-45ff-b9ec-ec3ab58ca1b8"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of the label.</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <paragraph>Increased     susceptibility to infection, lymphoma, and malignancy [<content styleCode="italics">see <linkHtml href="#Section_0">Boxed Warning</linkHtml>
                           </content>, <content styleCode="italics">Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)</content>]</paragraph>
                     </item>
                     <item>
                        <paragraph>Excess     mortality, graft loss, and hepatic artery thrombosis in liver transplant     patients [<content styleCode="italics">see <linkHtml href="#Section_0">Boxed Warning</linkHtml>
                           </content>, <content styleCode="italics">Warnings     and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)</content>]</paragraph>
                     </item>
                     <item>
                        <paragraph>Bronchial     anastomotic dehiscence in lung transplant patients [<content styleCode="italics">see <linkHtml href="#Section_0">Boxed Warning</linkHtml>
                           </content>, <content styleCode="italics">Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)</content>]</paragraph>
                     </item>
                     <item>
                        <paragraph>Hypersensitivity     reactions [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)</content>]</paragraph>
                     </item>
                     <item>
                        <paragraph>Exfoliative     dermatitis [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)</content>]</paragraph>
                     </item>
                     <item>
                        <paragraph>Angioedema     [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.5">5.5</linkHtml>)</content>]</paragraph>
                     </item>
                     <item>
                        <paragraph>Fluid     accumulation and impairment of wound healing [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.6">5.6</linkHtml>)</content>]</paragraph>
                     </item>
                     <item>
                        <paragraph>Hypertriglyceridemia,     hypercholesterolemia [<content styleCode="italics">see Warnings and     Precautions (<linkHtml href="#Section_5.7">5.7</linkHtml>)</content>]</paragraph>
                     </item>
                     <item>
                        <paragraph>Decline     in renal function in long-term combination of cyclosporine with sirolimus [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.8">5.8</linkHtml>)</content>]</paragraph>
                     </item>
                     <item>
                        <paragraph>Proteinuria     [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.9">5.9</linkHtml>)</content>]</paragraph>
                     </item>
                     <item>
                        <paragraph>Interstitial     lung disease [<content styleCode="italics">see Warnings and     Precautions (<linkHtml href="#Section_5.11">5.11</linkHtml>)</content>]</paragraph>
                     </item>
                     <item>
                        <paragraph>Increased     risk of calcineurin inhibitor-induced HUS/TTP/TMA [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.13">5.13</linkHtml>)</content>]</paragraph>
                     </item>
                     <item>
                        <paragraph>Embryo-fetal     toxicity [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.15">5.15</linkHtml>)</content>]</paragraph>
                     </item>
                     <item>
                        <paragraph>Male     infertility [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.16">5.16</linkHtml>)</content>]</paragraph>
                     </item>
                  </list>
                  <paragraph>The most common (≥30%) adverse reactions observed with sirolimus in clinical studies for organ rejection prophylaxis in recipients of renal transplantation are: peripheral edema, hypertriglyceridemia, hypertension, hypercholesterolemia, creatinine increased, constipation, abdominal pain, diarrhea, headache, fever, urinary tract infection, anemia, nausea, arthralgia, pain, and thrombocytopenia.</paragraph>
                  <paragraph>The most common (≥20%) adverse reactions observed with sirolimus in the clinical study for the treatment of LAM are: stomatitis, diarrhea, abdominal pain, nausea, nasopharyngitis, acne, chest pain, peripheral edema, upper respiratory tract infection, headache, dizziness, myalgia, and hypercholesterolemia.</paragraph>
                  <paragraph> The following adverse reactions resulted in a rate of discontinuation of &gt;5% in clinical trials for renal transplant rejection prophylaxis: creatinine increased, hypertriglyceridemia, and TTP. In patients with LAM, 11% of subjects discontinued due to adverse reactions, with no single adverse reaction leading to discontinuation in more than one patient being treated with sirolimus.</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20231205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Prophylaxis of organ rejection in patients receiving renal transplants: Most common adverse reactions (incidence ≥30%) are peripheral edema, hypertriglyceridemia, hypertension, hypercholesterolemia, creatinine increased, abdominal pain, diarrhea, headache, fever, urinary tract infection, anemia, nausea, arthralgia, pain, and thrombocytopenia (<linkHtml href="#Section_6">6</linkHtml>).</paragraph>
                        <paragraph>Lymphangioleiomyomatosis: Most common adverse reactions (incidence ≥20%) are stomatitis, diarrhea, abdominal pain, nausea, nasopharyngitis, acne, chest pain, peripheral edema, upper respiratory tract infection, headache, dizziness, myalgia, and hypercholesterolemia (<linkHtml href="#Section_6.6">6.6</linkHtml>).</paragraph>
                        <paragraph> <content styleCode="bold"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <content styleCode="underline">www.fda.gov/medwatch</content>
                              </content>
                           </content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="1d6236f6-c3f8-428a-aae1-756585426b36"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.1 Clinical Studies Experience in Prophylaxis of Organ Rejection Following Renal Transplantation</title>
                     <text>
                        <paragraph>The safety and efficacy of Sirolimus oral solution for the prevention of organ rejection following renal transplantation were assessed in two randomized, double-blind, multicenter, controlled trials [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.1">14.1</linkHtml>)</content>]. The safety profiles in the two studies were similar.</paragraph>
                        <paragraph>The incidence of adverse reactions in the randomized, double-blind, multicenter, placebo-controlled trial (Study 2) in which 219 renal transplant patients received sirolimus oral solution 2 mg/day, 208 received sirolimus oral solution 5 mg/day, and 124 received placebo is presented in Table 1 below. The study population had a mean age of 46 years (range 15 to 71 years), the distribution was 67% male, and the composition by race was: White (78%), Black (11%), Asian (3%), Hispanic (2%), and Other (5%). All patients were treated with cyclosporine and corticosteroids. Data (≥ 12 months post-transplant) presented in the following table show the adverse reactions that occurred in at least one of the sirolimus treatment groups with an incidence of ≥20%.</paragraph>
                        <paragraph>The safety profile of the tablet did not differ from that of the oral solution formulation [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.1">14.1</linkHtml>)</content>].</paragraph>
                        <paragraph>In general, adverse reactions related to the administration of sirolimus were dependent on dose/concentration. Although a daily maintenance dose of 5 mg, with a loading dose of 15 mg, was shown to be safe and effective, no efficacy advantage over the 2 mg dose could be established for renal transplant patients. Patients receiving 2 mg of sirolimus oral solution per day demonstrated an overall better safety profile than did patients receiving 5 mg of sirolimus oral solution per day.</paragraph>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 1: ADVERSE REACTIONS OCCURRING AT A FREQUENCY OF ≥20% IN AT LEAST ONE OF THE SIROLIMUS TREATMENT GROUPS IN A STUDY OF PROPHYLAXIS OF ORGAN REJECTION FOLLOWING RENAL TRANSPLANTATION (%) AT ≥ 12 MONTHS POST-TRANSPLANTATION (STUDY 2)<sup>a</sup>
                           </content>
                        </paragraph>
                        <paragraph>                                                                                                                             </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="0">
                           <colgroup>
                              <col width=""/>
                              <col width=""/>
                              <col width=""/>
                              <col width=""/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2" valign="middle"> Adverse Reaction <br/>  <br/> </td>
                                 <td styleCode="Rrule" colspan="3" valign="middle"> ––– Sirolimus Oral Solution––– <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="middle">  2 mg/day <br/> (n = 218)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 5 mg/day<br/> (n = 208) <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> Placebo<br/> (n = 124) <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Peripheral             edema<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 54<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 58<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 48<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Hypertriglyceridemia<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 45<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 57<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 23<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Hypertension<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 45<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 49<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 48<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Hypercholesterolemia<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 43<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 46<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 23<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Creatinine             increased<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 39<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 40<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 38<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Constipation<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 36<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 38<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 31<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Abdominal pain<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 29<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 36<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 30<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Diarrhea<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 25<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 35<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 27<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Headache<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 34<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 34<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 31<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Fever<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 23<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 34<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 35<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Urinary tract             infection<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 26<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 33<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 26<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Anemia<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 23<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 33<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 21<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Nausea<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 25<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 31<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 29<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Arthralgia<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 25<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 31<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 18<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Thrombocytopenia<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 14<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 30<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 9<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Pain<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 33<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 29<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 25<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Acne<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 22<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 22<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 19<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Rash<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 10<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 20<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 6<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> Edema<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 20<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 18<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 15<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>a: Patients received cyclosporine and corticosteroids.</paragraph>
                        <paragraph>The following adverse reactions were reported less frequently (≥3%, but &lt;20%)</paragraph>
                        <paragraph>• <content styleCode="bold">
                              <content styleCode="italics">Body as a Whole –</content>
                           </content> Sepsis, lymphocele, herpes zoster, herpes simplex.<br/>• <content styleCode="bold">Cardiovascular </content>– Venous thromboembolism (including pulmonary embolism, deep venous thrombosis), tachycardia.<br/>• <content styleCode="bold">Digestive System</content> – Stomatitis.<br/>• <content styleCode="bold">Hematologic and Lymphatic System</content> – Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), leukopenia.<br/>• <content styleCode="bold">Metabolic/Nutritional </content>– Abnormal healing, increased lactic dehydrogenase (LDH), hypokalemia, diabetes mellitus.<br/>• <content styleCode="bold">Musculoskeletal System</content> – Bone necrosis.<br/>• <content styleCode="bold">Respiratory System</content> – Pneumonia, epistaxis.<br/>• <content styleCode="bold">Skin </content>– Melanoma, squamous cell carcinoma, basal cell carcinoma.<br/>• <content styleCode="bold">Urogenital System</content> – Pyelonephritis, decline in renal function (creatinine increased) in long-term combination of cyclosporine with sirolimus <content styleCode="italics">[see <linkHtml href="#Section_5.8">Warnings and Precautions (5.8)</linkHtml>],</content> ovarian cysts, menstrual disorders (including amenorrhea and menorrhagia).</paragraph>
                        <paragraph>Less frequently (&lt;3%) occurring adverse reactions included: lymphoma/post-transplant lymphoproliferative disorder, mycobacterial infections (including <content styleCode="italics">M. tuberculosis</content>), pancreatitis, cytomegalovirus (CMV), and Epstein-Barr virus.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Increased Serum Cholesterol and Triglycerides</content>
                        </paragraph>
                        <paragraph>The use of sirolimus in renal transplant patients was associated with increased serum cholesterol and triglycerides that may require treatment.</paragraph>
                        <paragraph>In Studies 1 and 2, in <content styleCode="italics">de novo </content>renal transplant patients who began the study with fasting, total serum cholesterol &lt;200 mg/dL or fasting, total serum triglycerides &lt;200 mg/dL, there was an increased incidence of hypercholesterolemia (fasting serum cholesterol &gt;240 mg/dL) or hypertriglyceridemia (fasting serum triglycerides &gt;500 mg/dL), respectively, in patients receiving both sirolimus 2 mg and sirolimus 5 mg compared with azathioprine and placebo controls.</paragraph>
                        <paragraph>Treatment of new-onset hypercholesterolemia with lipid-lowering agents was required in 42-52% of patients enrolled in the sirolimus arms of Studies 1 and 2 compared with 16% of patients in the placebo arm and 22% of patients in the azathioprine arm. In other sirolimus renal transplant studies, up to 90% of patients required treatment for hyperlipidemia and hypercholesterolemia with anti-lipid therapy (e.g., statins, fibrates). Despite anti-lipid management, up to 50% of patients had fasting serum cholesterol levels &gt;240 mg/dL and triglycerides above recommended target levels [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.7">5.7</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Abnormal Healing</content>
                        </paragraph>
                        <paragraph>Abnormal healing events following transplant surgery include fascial dehiscence, incisional hernia, and anastomosis disruption (e.g., wound, vascular, airway, ureteral, biliary).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Malignancies</content>
                        </paragraph>
                        <paragraph>Table 2 below summarizes the incidence of malignancies in the two controlled trials (Studies 1 and 2) for the prevention of acute rejection [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.1">14.1</linkHtml>)</content>].</paragraph>
                        <paragraph>At 24 months (Study 1) and 36 months (Study 2) post-transplant, there were no significant differences among treatment groups.</paragraph>
                        <paragraph> <content styleCode="bold">TABLE 2: INCIDENCE (%) OF MALIGNANCIES IN STUDY 1 (24 MONTHS) AND STUDY 2 (36 MONTHS) POST-TRANSPLANT<sup>a,b</sup>
                           </content>
                           <br/>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="0">
                           <colgroup>
                              <col width=""/>
                              <col width="15.4791562863312%"/>
                              <col width="15.1802026241488%"/>
                              <col width="18.252781929912%"/>
                              <col width="15.9109782428168%"/>
                              <col width="18.4686929081548%"/>
                              <col width="16.7081880086364%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle"> Malignancy<br/> </td>
                                 <td styleCode="Rrule" colspan="2" align="center" valign="middle"> Sirolimus<br/> Oral Solution<br/> 2 mg/day<br/> </td>
                                 <td styleCode="Rrule" colspan="2" align="center" valign="middle"> Sirolimus<br/> Oral Solution<br/> 5 mg/day<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> Azathioprine<br/> 2-3 mg/kg/day<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> Study 1<br/> (n = 284)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> Study 2<br/> (n = 227)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> Study 1<br/> (n = 274)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> Study 2<br/> (n = 219)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> Study 1<br/> (n = 161)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> Placebo<br/> Study 2<br/> (n = 130)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Lymphoma/lymphoproliferative             disease</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">0.7</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">1.8</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">1.1</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">3.2</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">0.6</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">0.8</content>
                                    <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Skin             Carcinoma</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Any             Squamous Cell<sup>c</sup>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.4<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 2.7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 2.2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.9<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 3.8<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 3.0<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Any             Basal Cell<sup>c</sup>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 2.2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 1.5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 1.8<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 2.5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 5.3<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Melanoma<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.4<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 1.4<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.0<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Miscellaneous/Not             Specified<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.8<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Total</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">1.1</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">4.4</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">3.3</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">4.1</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">4.3</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">7.7</content>
                                    <br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Other             Malignancy</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">1.1</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">2.2</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">1.5</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">1.4</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">0.6</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">2.3</content>
                                    <br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>a: Patients received cyclosporine and corticosteroids.</paragraph>
                        <paragraph>b: Includes patients who prematurely discontinued treatment.</paragraph>
                        <paragraph> c: Patients may be counted in more than one category.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="17517848-f6c3-4b43-bc83-de94eaf86551"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.2 Sirolimus Oral Solution Following Cyclosporine Withdrawal</title>
                     <text>
                        <paragraph>The incidence of adverse reactions was determined through 36 months in a randomized, multicenter, controlled trial (Study 3) in which 215 renal transplant patients received sirolimus as a maintenance regimen following cyclosporine withdrawal, and 215 patients received sirolimus with cyclosporine therapy [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.2">14.2</linkHtml>)</content>]. All patients were treated with corticosteroids. The safety profile prior to randomization (start of cyclosporine withdrawal) was similar to that of the 2 mg sirolimus groups in Studies 1 and 2.</paragraph>
                        <paragraph>Following randomization (at 3 months), patients who had cyclosporine eliminated from their therapy experienced higher incidences of the following adverse reactions: abnormal liver function tests (including increased AST/SGOT and increased ALT/SGPT), hypokalemia, thrombocytopenia, and abnormal healing. Conversely, the incidence of the following adverse events was higher in patients who remained on cyclosporine than those who had cyclosporine withdrawn from therapy: hypertension, cyclosporine toxicity, increased creatinine, abnormal kidney function, toxic nephropathy, edema, hyperkalemia, hyperuricemia, and gum hyperplasia. Mean systolic and diastolic blood pressure improved significantly following cyclosporine withdrawal.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Malignancies</content>
                        </paragraph>
                        <paragraph>The incidence of malignancies in Study 3 [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.2">14.2</linkHtml>)</content>] is presented in Table 3.</paragraph>
                        <paragraph>In Study 3, the incidence of lymphoma/lymphoproliferative disease was similar in all treatment groups. The overall incidence of malignancy was higher in patients receiving sirolimus plus cyclosporine compared with patients who had cyclosporine withdrawn. Conclusions regarding these differences in the incidence of malignancy could not be made because Study 3 was not designed to consider malignancy risk factors or systematically screen subjects for malignancy. In addition, more patients in the sirolimus with cyclosporine group had a pre-transplantation history of skin carcinoma.</paragraph>
                        <paragraph> <content styleCode="bold">TABLE 3: INCIDENCE (%) OF MALIGNANCIES IN STUDY 3 (CYCLOSPORINE WITHDRAWAL STUDY) AT 36 MONTHS POST-TRANSPLANT<sup>a,b</sup>
                           </content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="0">
                           <colgroup>
                              <col width=""/>
                              <col width="37.252652710066%"/>
                              <col width="31.4597074849441%"/>
                              <col width="31.28763980499%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Malignancy<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> Nonrandomized<br/> (n = 95)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> Sirolimus with             Cyclosporine<br/>Therapy<br/>(n = 215)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> Sirolimus Following Cyclosporine Withdrawal<br/> (n = 215)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Lymphoma/lymphoproliferative             disease</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">1.1</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">1.4</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">0.5</content>
                                    <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Skin             Carcinoma</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Any             Squamous Cellc<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 3.2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 3.3<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 2.3<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Any             Basal Cellc<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 3.2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 6.5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 2.3<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Melanoma<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.0<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Miscellaneous/Not             Specified<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 1.1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.9<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> 0.0<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Total</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">
                                       <content styleCode="bold">4.2</content>
                                    </content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">
                                       <content styleCode="bold">7.9</content>
                                    </content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">
                                       <content styleCode="bold">3.7</content>
                                    </content>
                                    <br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Other             Malignancy</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">
                                       <content styleCode="bold">3.2</content>
                                    </content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">
                                       <content styleCode="bold">3.3</content>
                                    </content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="middle"> <content styleCode="bold">
                                       <content styleCode="bold">1.9</content>
                                    </content>
                                    <br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>a: Patients received cyclosporine and corticosteroids.</paragraph>
                        <paragraph>b: Includes patients who prematurely discontinued treatment.</paragraph>
                        <paragraph>c: Patients may be counted in more than one category.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.3">
                     <id root="944182cc-b734-430b-8ca6-93fbf9a8cb88"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.3 High-Immunologic Risk Renal Transplant Patients</title>
                     <text>
                        <paragraph>Safety was assessed in 224 patients who received at least one dose of sirolimus with cyclosporine [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.3">14.3</linkHtml>)</content>]. Overall, the incidence and nature of adverse reactions was similar to those seen in previous combination studies with sirolimus. The incidence of malignancy was 1.3% at 12 months.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.4">
                     <id root="dfc5d55d-706f-4393-b42a-3d81df801e51"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.4 Conversion from Calcineurin Inhibitors to Sirolimus Oral Solution in Maintenance Renal Transplant Population</title>
                     <text>
                        <paragraph>The safety and efficacy of conversion from calcineurin inhibitors to sirolimus in maintenance renal transplant population have not been established [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.4">14.4</linkHtml>)</content>]. In a study evaluating the safety and efficacy of conversion from calcineurin inhibitors to sirolimus (initial target sirolimus concentrations of 12-20 ng/mL, and then 8-20 ng/mL, by chromatographic assay) in maintenance renal transplant patients, enrollment was stopped in the subset of patients (n = 87) with a baseline glomerular filtration rate of less than 40 mL/min. There was a higher rate of serious adverse events, including pneumonia, acute rejection, graft loss and death, in this stratum of the sirolimus treatment arm. </paragraph>
                        <paragraph>The subset of patients with a baseline glomerular filtration rate of less than 40 mL/min had 2 years of follow-up after randomization. In this population, the rate of pneumonia was 25.9% (15/58) versus 13.8% (4/29), graft loss (excluding death with functioning graft loss) was 22.4% (13/58) versus 31.0% (9/29), and death was 15.5% (9/58) versus 3.4% (1/29) in the sirolimus conversion group and CNI continuation group, respectively.</paragraph>
                        <paragraph>In the subset of patients with a baseline glomerular filtration rate of greater than 40 mL/min, there was no benefit associated with conversion with regard to improvement in renal function and a greater incidence of proteinuria in the sirolimus conversion arm.</paragraph>
                        <paragraph>Overall in this study, a 5-fold increase in the reports of tuberculosis among sirolimus 2.0% (11/551) and comparator 0.4% (1/273) treatment groups was observed with 2:1 randomization scheme.</paragraph>
                        <paragraph> In a second study evaluating the safety and efficacy of conversion from tacrolimus to sirolimus 3 to 5 months post-kidney transplant, a higher rate of adverse events, discontinuations due to adverse events, acute rejection, and new onset diabetes mellitus was observed following conversion to sirolimus. There was also no benefit with respect to renal function and a greater incidence of proteinuria was observed after conversion to sirolimus <content styleCode="italics">[(see Clinical Studies (<linkHtml href="#Section_14.4">14.4</linkHtml>
                           </content>)<content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.5">
                     <id root="6e405756-900f-4f23-a972-f67599e6227e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.5 Pediatric Renal Transplant Patients</title>
                     <text>
                        <paragraph>Safety was assessed in a controlled clinical trial in pediatric (&lt;18 years of age) renal transplant patients considered at high-immunologic risk, defined as a history of one or more acute allograft rejection episodes and/or the presence of chronic allograft nephropathy on a renal biopsy [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.6">14.6</linkHtml>)</content>]. The use of sirolimus in combination with calcineurin inhibitors and corticosteroids was associated with a higher incidence of deterioration of renal function (creatinine increased) compared to calcineurin inhibitor-based therapy, serum lipid abnormalities (including, but not limited to, increased serum triglycerides and cholesterol), and urinary tract infections.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.6">
                     <id root="f361e14e-a37f-4197-a45f-e39055dde420"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.6 Patients with Lymphangioleiomyomatosis</title>
                     <text>
                        <paragraph>Safety was assessed in a controlled trial involving 89 patients with lymphangioleiomyomatosis, 46 of whom were treated with sirolimus [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.7">14.7</linkHtml>)</content>]. The adverse drug reactions observed in this trial were consistent with the known safety profile for renal transplant patients receiving sirolimus, with the addition of weight decreased which was reported at a greater incidence with sirolimus when compared to placebo. Adverse reactions occurring at a frequency of ≥20% in the sirolimus treatment group and greater than placebo include stomatitis, diarrhea, abdominal pain, nausea, nasopharyngitis, acne, chest pain, peripheral edema, upper respiratory tract infection, headache, dizziness, myalgia, and hypercholesterolemia.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.7">
                     <id root="c2e04d5f-cded-4216-a197-e3ce25d89e37"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>6.7 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of sirolimus in transplant patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">• Body as a Whole</content>
                           </content> – Lymphedema.</paragraph>
                        <paragraph>• <content styleCode="bold">
                              <content styleCode="italics">Cardiovascular</content>
                           </content> – Pericardial effusion (including hemodynamically significant effusions and tamponade requiring intervention in children and adults) and fluid accumulation.</paragraph>
                        <paragraph>•  <content styleCode="bold">
                              <content styleCode="italics">Digestive System</content>
                           </content> – Ascites.</paragraph>
                        <paragraph>•  <content styleCode="bold">
                              <content styleCode="italics">Hematological/Lymphatic</content>
                           </content> – Pancytopenia, neutropenia.</paragraph>
                        <paragraph>• <content styleCode="bold">
                              <content styleCode="italics">Hepatobiliary Disorders</content>
                           </content> – Hepatotoxicity, including fatal hepatic necrosis, with elevated sirolimus trough concentrations.</paragraph>
                        <paragraph>• <content styleCode="bold">
                              <content styleCode="italics">Immune System</content>
                           </content> – Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, angioedema, and hypersensitivity vasculitis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>• <content styleCode="bold">
                              <content styleCode="italics">Infections </content>
                           </content>– Tuberculosis. BK virus associated nephropathy has been observed in patients receiving immunosuppressants, including sirolimus. This infection may be associated with serious outcomes, including deteriorating renal function and renal graft loss. Cases of progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with immunosuppressants, including sirolimus <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.10">5.10</linkHtml>)].</content>
                           <content styleCode="italics">Clostridium difficile enterocolitis</content>.</paragraph>
                        <paragraph>• <content styleCode="bold">
                              <content styleCode="italics">Metabolic/Nutritional</content>
                           </content> – Liver function test abnormal, AST/SGOT increased, ALT/SGPT increased, hypophosphatemia, hyperglycemia, diabetes mellitus.</paragraph>
                        <paragraph>• <content styleCode="bold">
                              <content styleCode="italics">Nervous system</content>
                           </content> - Posterior reversible encephalopathy syndrome.</paragraph>
                        <paragraph>• <content styleCode="bold">
                              <content styleCode="italics">Respiratory</content>
                           </content> – Cases of interstitial lung disease (including pneumonitis, bronchiolitis obliterans organizing pneumonia [BOOP], and pulmonary fibrosis), some fatal, with no identified infectious etiology have occurred in patients receiving immunosuppressive regimens including sirolimus. In some cases, the interstitial lung disease has resolved upon discontinuation or dose reduction of sirolimus. The risk may be increased as the sirolimus trough concentration increases [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.11">5.11</linkHtml>)</content>]<content styleCode="italics">;</content> pulmonary hemorrhage; pleural effusion; alveolar proteinosis.</paragraph>
                        <paragraph>• <content styleCode="bold">
                              <content styleCode="italics">Skin</content>
                           </content> – Neuroendocrine carcinoma of the skin (Merkel cell carcinoma) [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.18">5.18</linkHtml>)</content>], exfoliative dermatitis [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph> • <content styleCode="bold">
                              <content styleCode="italics">Urogenital</content>
                           </content> – Nephrotic syndrome, proteinuria, focal segmental glomerulosclerosis, ovarian cysts, menstrual disorders (including amenorrhea and menorrhagia). Azoospermia has been reported with the use of sirolimus and has been reversible upon discontinuation of sirolimus in most cases.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="18731a8c-72fd-4254-bdc5-b34a312778d1"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Sirolimus is known to be a substrate for both cytochrome P-450 3A4 (CYP3A4) and p-glycoprotein (P-gp). Inducers of CYP3A4 and P-gp may decrease sirolimus concentrations whereas inhibitors of CYP3A4 and P-gp may increase sirolimus concentrations.</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20231205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <paragraph>Avoid concomitant use with strong CYP3A4/P-gp     inducers or strong CYP3A4/P-gp inhibitors that decrease or increase sirolimus     concentrations (<linkHtml href="#Section_7.4">7.4</linkHtml>,<linkHtml href="#Section_12.3">12.3</linkHtml>).</paragraph>
                           </item>
                           <item>
                              <paragraph>Therapeutic drug monitoring and dose reduction for sirolimus should be considered when sirolimus is co-administered with cannabidiol (<linkHtml href="#Section_5.21">5.21</linkHtml>,<linkHtml href="#Section_7.5">7.5</linkHtml>). </paragraph>
                           </item>
                           <item>
                              <paragraph>See full prescribing information for complete list of clinically significant drug interactions (<linkHtml href="#Section_12.3">12.3</linkHtml>).</paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.1">
                     <id root="4fa99324-df5a-4158-af22-1dc49f7bbd1a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.1 Use with Cyclosporine</title>
                     <text>
                        <paragraph>Cyclosporine, a substrate and inhibitor of CYP3A4 and P-gp, was demonstrated to increase sirolimus concentrations when co-administered with sirolimus. In order to diminish the effect of this interaction with cyclosporine, it is recommended that sirolimus be taken 4 hours after administration of cyclosporine oral solution (MODIFIED) and/or cyclosporine capsules (MODIFIED). If cyclosporine is withdrawn from combination therapy with sirolimus, higher doses of sirolimus are needed to maintain the recommended sirolimus trough concentration ranges [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.2">
                     <id root="9dc19144-5838-47b7-9a04-79340a07256e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.2 Strong Inducers and Strong Inhibitors of CYP3A4 and P-gp</title>
                     <text>
                        <paragraph>Avoid concomitant use of sirolimus with strong inducers (e.g., rifampin, rifabutin) and strong inhibitors (e.g., ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, clarithromycin) of CYP3A4 and P-gp. Alternative agents with lesser interaction potential with sirolimus should be considered [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.20">5.20</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.3">
                     <id root="4b6365f1-3612-4dbc-af89-9fc32726a427"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.3 Grapefruit Juice</title>
                     <text>
                        <paragraph>Because grapefruit juice inhibits the CYP3A4-mediated metabolism of sirolimus, it must not be taken with or be used for dilution of sirolimus [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.9">2.9</linkHtml>), Drug Interactions (<linkHtml href="#Section_7.3">7.3</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.4">
                     <id root="e6bc4846-6ea0-4f48-8ec8-e15a644b098e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.4 Weak and Moderate Inducers or Inhibitors of CYP3A4 and P-gp</title>
                     <text>
                        <paragraph>Exercise caution when using sirolimus with drugs or agents that are modulators of CYP3A4 and P-gp. The dosage of sirolimus and/or the co-administered drug may need to be adjusted <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)].</content>
                           <br/> • Drugs that could increase sirolimus blood concentrations:<br/>   Bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, letermovir, protease inhibitors (e.g., HIV and hepatitis C that include drugs such as ritonavir, indinavir, boceprevir, and telaprevir), metoclopramide, nicardipine, troleandomycin, verapamil<br/> • Drugs and other agents that could decrease sirolimus concentrations:<br/>   Carbamazepine, phenobarbital, phenytoin, rifapentine, St. John’s Wort (<content styleCode="italics">Hypericum perforatum</content>)<br/> • Drugs with concentrations that could increase when given with sirolimus: </paragraph>
                        <paragraph>  Verapamil</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.5">
                     <id root="0d3d623b-2119-44e5-a099-84ff635c9ce0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.5 Cannabidiol</title>
                     <text>
                        <br/>
                        <paragraph>The blood levels of sirolimus may increase upon concomitant use with cannabidiol. When cannabidiol and sirolimus are co-administered, closely monitor for an increase in sirolimus blood levels and for adverse reactions suggestive of sirolimus toxicity. A dose reduction of sirolimus should be considered as needed when sirolimus is co-administered with cannabidiol <content styleCode="italics">[<linkHtml href="#Section_2.5">see Dosage and Administration (2.5)</linkHtml> and <linkHtml href="#Section_5.21">Warnings and Precautions (5.21)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="e22c8f23-e11a-40a4-a37c-8ccbda8ce60f"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20231205"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <paragraph>Pregnancy: Based on animal data can cause fetal harm (<linkHtml href="#Section_5.15">5.15</linkHtml>,<linkHtml href="#Section_8.1">8.1</linkHtml>).</paragraph>
                           </item>
                           <item>
                              <paragraph>Lactation: Potential for serious adverse effects in     breastfed infants based on mechanism of action (<linkHtml href="#Section_8.6">8.2</linkHtml>).</paragraph>
                           </item>
                           <item>
                              <paragraph>Females and Males of Reproductive Potential: May impair fertility (<linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#Section_8.7">8.3</linkHtml>,<linkHtml href="#Section_13.1">13.1</linkHtml>).</paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="14031059-5160-4623-8e60-c7ac0ff570a4"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on animal studies and the mechanism of action, sirolimus can cause fetal harm when administered to a pregnant woman [<content styleCode="italics">see Data, Clinical Pharmacology (<linkHtml href="#Section_12.1">12.1</linkHtml>)</content>]. There are limited data on the use of sirolimus during pregnancy; however, these data are insufficient to inform a drug-associated risk of adverse developmental outcomes. In animal studies, sirolimus was embryo/fetotoxic in rats at sub-therapeutic doses [<content styleCode="italics">see Data</content>]. Advise pregnant women of the potential risk to a fetus.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Sirolimus crossed the placenta and was toxic to the conceptus.</paragraph>
                        <paragraph>In rat embryo-fetal development studies, pregnant rats were administered sirolimus orally during the period of organogenesis (Gestational Day 6-15). Sirolimus produced embryo-fetal lethality at 0.5 mg/kg (2.5-fold the clinical dose of 2 mg, on a body surface area basis) and reduced fetal weight at 1 mg/kg (5-fold the clinical dose of 2 mg). The no observed adverse effect level (NOAEL) for fetal toxicity in rats was 0.1 mg/kg (0.5-fold the clinical dose of 2 mg). Maternal toxicity (weight loss) was observed at 2 mg/kg (10-fold the clinical dose of 2 mg). The NOAEL for maternal toxicity was 1 mg/kg. In combination with cyclosporine, rats had increased embryo-fetal mortality compared with sirolimus alone.</paragraph>
                        <paragraph>In rabbit embryo-fetal development studies, pregnant rabbits were administered sirolimus orally during the period of organogenesis (Gestational Day 6-18). There were no effects on embryo-fetal development at doses up to 0.05 mg/kg (0.5-fold the clinical dose of 2 mg, on a body surface area basis); however, at doses of 0.05 mg/kg and above, the ability to sustain a successful pregnancy was impaired (i.e., embryo-fetal abortion or early resorption). Maternal toxicity (decreased body weight) was observed at 0.05 mg/kg. The NOAEL for maternal toxicity was 0.025 mg/kg (0.25-fold the clinical dose of 2 mg).</paragraph>
                        <paragraph> In a pre- and post-natal development study in rats, pregnant females were dosed during gestation and lactation (Gestational Day 6 through Lactation Day 20). An increased incidence of dead pups, resulting in reduced live litter size, occurred at 0.5 mg/kg (2.5-fold the clinical dose of 2 mg/kg on a body surface area basis). At 0.1 mg/kg (0.5-fold the clinical dose of 2 mg), there were no adverse effects on offspring. Sirolimus did not cause maternal toxicity or affect developmental parameters in the surviving offspring (morphological development, motor activity, learning, or fertility assessment) at 0.5 mg/kg, the highest dose tested.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="67717c1c-6546-4c06-8029-96c45eb54bc4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>It is not known whether sirolimus is present in human milk. There are no data on its effects on the breastfed infant or milk production. The pharmacokinetic and safety profiles of sirolimus in infants are not known.</paragraph>
                        <paragraph> Sirolimus is present in the milk of lactating rats. There is potential for serious adverse effects from sirolimus in breastfed infants based on mechanism of action [<content styleCode="italics">see Clinical Pharmacology (<linkHtml href="#Section_12.1">12.1</linkHtml>)]. </content>The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for sirolimus and any potential adverse effects on the breastfed child from sirolimus.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.7">
                     <id root="aeab01ab-b4ce-45cb-b8d5-bc05418532ee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>Females should not be pregnant or become pregnant while receiving sirolimus. Advise females of reproductive potential that animal studies have been shown sirolimus to be harmful to the developing fetus. Females of reproductive potential are recommended to use highly effective contraceptive method. Effective contraception must be initiated before sirolimus therapy, during sirolimus therapy, and for 12 weeks after sirolimus therapy has been stopped [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.15">5.15</linkHtml>), Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph> Based on clinical findings and findings in animals, male and female fertility may be compromised by the treatment with sirolimus [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.7">6.7</linkHtml>), Nonclinical Toxicology (<linkHtml href="#Section_13.1">13.1</linkHtml>)</content>]. Ovarian cysts and menstrual disorders (including amenorrhea and menorrhagia) have been reported in females with the use of sirolimus. Azoospermia has been reported in males with the use of sirolimus and has been reversible upon discontinuation of sirolimus in most cases.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="2ed606d8-ed85-4ebc-a1dc-2df3e6df44df"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Renal Transplant</content>
                        </paragraph>
                        <paragraph>The safety and efficacy of sirolimus in pediatric patients &lt;13 years have not been established.</paragraph>
                        <paragraph>The safety and efficacy of sirolimus oral solution and sirolimus tablets have been established for prophylaxis of organ rejection in renal transplantation in children ≥13 years judged to be at low- to moderate- immunologic risk. Use of sirolimus oral solution and sirolimus tablets in this subpopulation of children ≥ 13 years is supported by evidence from adequate and well-controlled trials of sirolimus oral solution in adults with additional pharmacokinetic data in pediatric renal transplantation patients [<content styleCode="italics">see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>].</paragraph>
                        <paragraph>Safety and efficacy information from a controlled clinical trial in pediatric and adolescent (&lt; 18 years of age) renal transplant patients judged to be at high-immunologic risk, defined as a history of one or more acute rejection episodes and/or the presence of chronic allograft nephropathy, do not support the chronic use of sirolimus oral solution or Tablets in combination with calcineurin inhibitors and corticosteroids, due to the higher incidence of lipid abnormalities and deterioration of renal function associated with these immunosuppressive regimens compared to calcineurin inhibitors, without increased benefit with respect to acute rejection, graft survival, or patient survival [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.6">14.6</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Lymphangioleiomyomatosis</content>
                        </paragraph>
                        <paragraph> The safety and efficacy of sirolimus in pediatric patients &lt;18 years have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="f963bf7d-efb5-46a8-9042-b18afc16fb6e"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of sirolimus oral solution or Tablets did not include sufficient numbers of patients ≥65 years to determine whether they respond differently from younger patients. Data pertaining to sirolimus trough concentrations suggest that dose adjustments based upon age in geriatric renal patients are not necessary.</paragraph>
                        <paragraph>Differences in responses between the elderly and younger patients have not been identified. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.8">
                     <id root="15bd1bf1-251b-441f-a99e-9970a8923bdc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.6 Patients with Hepatic Impairment</title>
                     <text>
                        <paragraph>The maintenance dose of sirolimus should be reduced in patients with hepatic impairment [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.7">2.7</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.9">
                     <id root="355a93f0-91a1-469b-84e3-136954511b85"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.7 Patients with Renal Impairment</title>
                     <text>
                        <paragraph>Dosage adjustment is not required in patients with renal impairment [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.8">2.8</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="6afaa816-eaf6-48a6-b6f3-0fa6b874e1d1"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <br/>
                  <paragraph>Reports of overdose with sirolimus have been received; however, experience has been limited. In general, the adverse effects of overdose are consistent with those listed in the adverse reactions section [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6">6</linkHtml>)</content>].</paragraph>
                  <paragraph> General supportive measures should be followed in all cases of overdose. Based on the low aqueous solubility and high erythrocyte and plasma protein binding of sirolimus, it is anticipated that sirolimus is not dialyzable to any significant extent. In mice and rats, the acute oral LD<sub>50</sub> was greater than 800 mg/kg.</paragraph>
               </text>
               <effectiveTime value="20231205"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="e7ff832d-7628-43bc-b9ab-b55a326dc5aa"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Sirolimus is an mTOR inhibitor immunosuppressive agent. Sirolimus is a macrocyclic lactone produced by <content styleCode="italics">Streptomyces hygroscopicus</content>. The chemical name of sirolimus (also known as rapamycin) is (3<content styleCode="italics">S</content>,6<content styleCode="italics">R</content>,7<content styleCode="italics">E</content>,9<content styleCode="italics">R</content>,10<content styleCode="italics">R</content>,12<content styleCode="italics">R</content>,14<content styleCode="italics">S</content>,15<content styleCode="italics">E</content>,17<content styleCode="italics">E</content>,19<content styleCode="italics">E</content>,21<content styleCode="italics">S</content>,23<content styleCode="italics">S</content>,26<content styleCode="italics">R</content>,27<content styleCode="italics">R</content>,34a<content styleCode="italics">S</content>)­-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1<content styleCode="italics">R</content>)-2-[(1<content styleCode="italics">S</content>,3<content styleCode="italics">R</content>,4<content styleCode="italics">R</content>)-4­hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy­3<content styleCode="italics">H</content>-pyrido[2,1-c][1,4] oxaazacyclohentriacontine-1,5,11,28,29 (4<content styleCode="italics">H</content>,6<content styleCode="italics">H</content>,31<content styleCode="italics">H</content>)-pentone. Its molecular formula is C<sub>51</sub>H<sub>79</sub>NO<sub>13</sub> and its molecular weight is 914.2. The structural formula of sirolimus is illustrated as follows.</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <br/>
                  <paragraph>Sirolimus is a white to off-white powder Freely soluble in Chloroform, acetone, methanol, methylene dichloride and acetonitrile. Soluble in ethanol and ethyl acetate. Insoluble in water.</paragraph>
                  <paragraph>Sirolimus is available for administration as an oral solution containing 1 mg/mL sirolimus. </paragraph>
                  <paragraph> The inactive ingredients in sirolimus oral solution are Phosal 50 PG<sup>®</sup> (phosphatidylcholine, propylene glycol, sunflower seed oil glyceride, ethanol, soy fatty acids, ascorbyl palmitate and tocopherol) and polysorbate 80. Sirolimus oral solution contains 1.5% - 2.5% ethanol.</paragraph>
               </text>
               <effectiveTime value="20231205"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>sirolimus-structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sirolimus-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="ee6cf017-867d-463a-a869-d36f785fbdd8"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20231205"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="32eb9deb-9b55-445b-b8fb-c3642cfc76e9"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Sirolimus inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin [IL]-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G<sub>1</sub>to the S phase of the cell cycle.</paragraph>
                        <paragraph>Mammalian target of rapamycin (mTOR) inhibitors such as sirolimus have been shown <content styleCode="italics">in vitro </content>to inhibit production of certain growth factors that may affect angiogenesis, fibroblast proliferation, and vascular permeability.</paragraph>
                        <paragraph>Studies in experimental models show that sirolimus prolongs allograft (kidney, heart, skin, islet, small bowel, pancreatico-duodenal, and bone marrow) survival in mice, rats, pigs, and/or primates. Sirolimus reverses acute rejection of heart and kidney allografts in rats and prolongs the graft survival in presensitized rats. In some studies, the immunosuppressive effect of sirolimus lasts up to 6 months after discontinuation of therapy. This tolerization effect is alloantigen-specific.</paragraph>
                        <paragraph>In rodent models of autoimmune disease, sirolimus suppresses immune-mediated events associated with systemic lupus erythematosus, collagen-induced arthritis, autoimmune type I diabetes, autoimmune myocarditis, experimental allergic encephalomyelitis, graft-versus-host disease, and autoimmune uveoretinitis.</paragraph>
                        <paragraph> Lymphangioleiomyomatosis involves lung tissue infiltration with smooth muscle-like cells that harbor inactivating mutations of the tuberous sclerosis complex (TSC) gene (LAM cells). Loss of TSC gene function activates the mTOR signaling pathway, resulting in cellular proliferation and release of lymphangiogenic growth factors. Sirolimus inhibits the activated mTOR pathway and thus the proliferation of LAM cells.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="04c3b540-5dc8-46f8-9931-f6c76a2e0472"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Orally-administered sirolimus, at doses of 2 mg/day and 5 mg/day, significantly reduced the incidence of organ rejection in low- to moderate-immunologic risk renal transplant patients at 6 months following transplantation compared with either azathioprine or placebo [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14.1">14.1</linkHtml>)</content>]. There was no demonstrable efficacy advantage of a daily maintenance dose of 5 mg with a loading dose of 15 mg over a daily maintenance dose of 2 mg with a loading dose of 6 mg. Therapeutic drug monitoring should be used to maintain sirolimus drug levels within the target-range [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.5">2.5</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="bc6f7b42-bd6c-463d-a618-f81d36f81aa1"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Sirolimus pharmacokinetics activity have been determined following oral administration in healthy subjects, pediatric patients, hepatically impaired patients, and renal transplant patients.</paragraph>
                        <paragraph>The pharmacokinetic parameters of sirolimus in low- to moderate-immunologic risk adult renal transplant patients following multiple dosing with sirolimus 2 mg daily, in combination with cyclosporine and corticosteroids, is summarized in Table 4.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 4: MEAN ± SD STEADY STATE SIROLIMUS PHARMACOKINETIC PARAMETERS IN LOW-TO MODERATE-IMMUNOLOGIC RISK ADULT RENAL TRANSPLANT PATIENTS FOLLOWING SIROLIMUS 2 MG DAILY<sup>a,b</sup>
                           </content>
                        </paragraph>
                        <br/>
                        <paragraph>               </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="0">
                           <colgroup>
                              <col width="34.7594111253829%"/>
                              <col width="31.0246023120245%"/>
                              <col width="34.2159865625926%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3" align="center" valign="top">                                                                                                                            Multiple             Dose (daily dose)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Solution<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Tablets<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> Cmax (ng/mL)             <br/> tmax (hr)<br/> AUC (ng•h/mL) <br/> Cmin (ng/mL)<sup>c</sup> <br/> CL/F (mL/h/kg)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 14.4 ± 5.3<br/> 2.1 ± 0.8<br/> 194 ± 78<br/> 7.1 ± 3.5<br/> 173 ± 50<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 15.0 ± 4.9<br/> 3.5 ± 2.4<br/> 230 ± 67<br/> 7.6 ± 3.1<br/> 139 ± 63<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>  </paragraph>
                        <paragraph>a: In presence of cyclosporine administered 4 hours before sirolimus dosing. </paragraph>
                        <paragraph>b: Based on data collected at months 1 and 3 post-transplantation.</paragraph>
                        <paragraph>c: Average C<sub>min</sub>over 6 months.</paragraph>
                        <paragraph>Whole blood trough sirolimus concentrations, as measured by LC/MS/MS in renal transplant patients, were significantly correlated with AUC<sub>τ,ss</sub>. Upon repeated, twice-daily administration without an initial loading dose in a multiple-dose study, the average trough concentration of sirolimus increases approximately 2- to 3-fold over the initial 6 days of therapy, at which time steady-state is reached. A loading dose of 3 times the maintenance dose will provide near steady-state concentrations within 1 day in most patients [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.3">2.3</linkHtml>, <linkHtml href="#Section_2.5">2.5</linkHtml>), Warning and Precautions (<linkHtml href="#Section_5.17">5.17</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Following administration of sirolimus oral solution, the mean times to peak concentration (t<sub>max</sub>) of sirolimus are approximately 1 hour and 2 hours in healthy subjects and renal transplant patients, respectively. The systemic availability of sirolimus is low, and was estimated to be approximately 14% after the administration of sirolimus oral solution. In healthy subjects, the mean bioavailability of sirolimus after administration of the tablet is approximately 27% higher relative to the solution. Sirolimus tablets are not bioequivalent to the solution; however, clinical equivalence has been demonstrated at the 2 mg dose level. Sirolimus concentrations, following the administration of sirolimus oral solution to stable renal transplant patients, are dose-proportional between 3 and 12 mg/m<sup>2</sup>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Food Effects</content>
                        </paragraph>
                        <paragraph>To minimize variability in sirolimus concentrations, both sirolimus oral solution and Tablets should be taken consistently with or without food [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2">2</linkHtml>)</content>]. In healthy subjects, a high-fat meal (861.8 kcal, 54.9% kcal from fat) increased the mean total exposure (AUC) of sirolimus by 23 to 35%, compared with fasting. The effect of food on the mean sirolimus C<sub>max</sub>was inconsistent depending on the sirolimus dosage form evaluated.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The mean (± SD) blood-to-plasma ratio of sirolimus was 36 ± 18 in stable renal allograft patients, indicating that sirolimus is extensively partitioned into formed blood elements. The mean volume of distribution (Vss/F) of sirolimus is 12 ± 8 L/kg. Sirolimus is extensively bound (approximately 92%) to human plasma proteins, mainly serum albumin (97%), α<sub>1</sub>-acid glycoprotein, and lipoproteins.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>Sirolimus is a substrate for both CYP3A4 and P-gp. Sirolimus is extensively metabolized in the intestinal wall and liver and undergoes counter-transport from enterocytes of the small intestine into the gut lumen. Inhibitors of CYP3A4 and P-gp increase sirolimus concentrations. Inducers of CYP3A4 and P-gp decrease sirolimus concentrations [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.20">5.20</linkHtml>) and Drug Interactions (<linkHtml href="#Section_7">7</linkHtml>)</content>]. Sirolimus is extensively metabolized by O-demethylation and/or hydroxylation. Seven (7) major metabolites, including hydroxy, demethyl, and hydroxydemethyl, are identifiable in whole blood. Some of these metabolites are also detectable in plasma, fecal, and urine samples. Sirolimus is the major component in human whole blood and contributes to more than 90% of the immunosuppressive activity.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Excretion</content>
                        </paragraph>
                        <paragraph>After a single dose of [<sup>14</sup>C] sirolimus oral solution in healthy volunteers, the majority (91%) of radioactivity was recovered from the feces, and only a minor amount (2.2%) was excreted in urine. The mean ± SD terminal elimination half-life (t½) of sirolimus after multiple dosing in stable renal transplant patients was estimated to be about 62 ± 16 hours.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Sirolimus Concentrations (Chromatographic Equivalent) Observed in Phase 3 Clinical Studies</content>
                        </paragraph>
                        <paragraph>The following sirolimus concentrations (chromatographic equivalent) were observed in phase 3 clinical studies for prophylaxis of organ rejection in <content styleCode="italics">de novo </content>renal transplant patients[<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14">14</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 5: SIROLIMUS WHOLE BLOOD TROUGH CONCENTRATIONS OBSERVED IN RENAL TRANSPLANT PATIENTS ENROLLED IN PHASE 3 STUDIES</content>
                        </paragraph>
                        <br/>
                        <paragraph>                                                          </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="0">
                           <colgroup>
                              <col width="31.9811875367431%"/>
                              <col width="16.1179698216735%"/>
                              <col width="9.77856163041348%"/>
                              <col width="16.1473642955124%"/>
                              <col width="11.1013129531648%"/>
                              <col width="14.8736037624927%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Patient             Population(Study number)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Treatment<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Mean<br/> (ng/mL)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Year 1<br/> 10<sup>th</sup> – 90<sup>th</sup> percentiles<br/> (ng/mL)<br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top">              Mean<br/> (ng/mL)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Year 3<br/>   10<sup>th</sup> – 90<sup>th</sup> percentiles<br/> (ng/mL)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Low-to-moderate             risk<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Sirolimus (2 mg/day) + CsA<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 7.2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 3.6 – 11<br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top"> -<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> -<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> (Studies 1 &amp; 2)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Sirolimus (5 mg/day)             + CsA<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 14<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 8 – 22<br/> </td>
                                 <td styleCode="Rrule" valign="top">                    -</td>
                                 <td styleCode="Rrule" align="left" valign="top">-<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Low-to-moderate<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Sirolimus + CsA<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 8.6<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 5 – 13a<br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top"> 9.1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 5.4 – 14<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> risk (Study 3)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Sirolimus alone<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 19<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 14 – 22a<br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top"> 16<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 11 – 22<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> High risk<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Sirolimus + CsA<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 15.7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 5.4 – 27.3b<br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top"> –<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> –<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> (Study 4)<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top"> 11.8<br/> 11.5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 6.2 – 16.9c<br/> 6.3 – 17.3d<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>  </paragraph>
                        <paragraph>a: Months 4 through 12</paragraph>
                        <paragraph>b: Up to Week 2; observed CsA Cmin was 217 (56 – 432) ng/mL</paragraph>
                        <paragraph>c: Week 2 to Week 26; observed CsA Cmin range was 174 (71 – 288) ng/mL</paragraph>
                        <paragraph>d: Week 26 to Week 52; observed CsA Cmin was 136 (54.5 – 218) ng/mL</paragraph>
                        <paragraph>The withdrawal of cyclosporine and concurrent increases in sirolimus trough concentrations to steady-state required approximately 6 weeks. Following cyclosporine withdrawal, larger sirolimus doses were required due to the absence of the inhibition of sirolimus metabolism and transport by cyclosporine and to achieve higher target sirolimus trough concentrations during concentration-controlled administration [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.1">2.1</linkHtml>), Drug Interactions (<linkHtml href="#Section_7.1">7.1</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="italics">Lymphangioleiomyomatosis</content>
                        </paragraph>
                        <paragraph>In a clinical trial of patients with lymphangioleiomyomatosis, the median whole blood sirolimus trough concentration after 3 weeks of receiving sirolimus tablets at a dose of 2 mg/day was 6.8 ng/mL (interquartile range 4.6 to 9.0 ng/mL; n = 37).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pharmacokinetics in Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>Sirolimus was administered as a single, oral dose to subjects with normal hepatic function and to patients with Child-Pugh classification A (mild), B (moderate), or C (severe) hepatic impairment. Compared with the values in the normal hepatic function group, the patients with mild, moderate, and severe hepatic impairment had 43%, 94%, and 189% higher mean values for sirolimus AUC, respectively, with no statistically significant differences in mean C<sub>max</sub>. As the severity of hepatic impairment increased, there were steady increases in mean sirolimus t<sub>1/2</sub>, and decreases in the mean sirolimus clearance normalized for body weight (CL/F/kg).</paragraph>
                        <paragraph>The maintenance dose of sirolimus should be reduced by approximately one third in patients with mild-to-moderate hepatic impairment and by approximately one half in patients with severe hepatic impairment [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.5">2.5</linkHtml>)</content>]. It is not necessary to modify the sirolimus loading dose in patients with mild, moderate, and severe hepatic impairment. Therapeutic drug monitoring is necessary in all patients with hepatic impairment [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.7">2.7</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Impairment</content>
                        </paragraph>
                        <paragraph>The effect of renal impairment on the pharmacokinetics of sirolimus is not known. However, there is minimal (2.2%) renal excretion of the drug or its metabolites in healthy volunteers. The loading and the maintenance doses of sirolimus need not be adjusted in patients with renal impairment [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.6">2.6</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Renal Transplant Patients</content>
                        </paragraph>
                        <paragraph>Sirolimus pharmacokinetic data were collected in concentration-controlled trials of pediatric renal transplant patients who were also receiving cyclosporine and corticosteroids. The target ranges for trough concentrations were either 10-20 ng/mL for the 21 children receiving tablets, or 5-15 ng/mL for the one child receiving oral solution. The children aged 6-11 years (n = 8) received mean ± SD doses of 1.75 ± 0.71 mg/day (0.064 ± 0.018 mg/kg, 1.65 ± 0.43 mg/m<sup>2</sup>). The children aged 12-18 years (n = 14) received mean ± SD doses of 2.79 ± 1.25 mg/day (0.053 ± 0.0150 mg/kg, 1.86 ± 0.61 mg/m<sup>2</sup>). At the time of sirolimus blood sampling for pharmacokinetic evaluation, the majority (80%) of these pediatric patients received the sirolimus dose at 16 hours after the once-daily cyclosporine dose. See Table 6 below.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 6: SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN ± SD) IN PEDIATRIC RENAL TRANSPLANT PATIENTS (MULTIPLE-DOSE CONCENTRATION CONTROL)<sup>a,b</sup>
                           </content>
                        </paragraph>
                        <br/>
                        <paragraph>                                   </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="0">
                           <colgroup>
                              <col width="7.0443496378609%"/>
                              <col width="4.61355293183848%"/>
                              <col width="9.66365710884016%"/>
                              <col width="13.3544994543109%"/>
                              <col width="13.2949697390614%"/>
                              <col width="12.7790455402322%"/>
                              <col width="13.6819128881834%"/>
                              <col width="13.5231669808513%"/>
                              <col width="12.0448457188213%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="top"> Age<br/> (y)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top">  <br/> n<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Body weight (kg)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Cmax,ss<br/> (ng/mL)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> tmax,ss<br/> (h)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Cmin,ss<br/> (ng/mL)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> AUCт,ss<br/> (ng•h/mL)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> CL/F<sup>c</sup>
                                    <br/> (mL/h/kg)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> CL/F<sup>c</sup>
                                    <br/> (L/h/m<sup>2</sup>)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="top"> 6-11<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> <br/>8 </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 27 ± 10<br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top"> 22.1 ± 8.9<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 5.88 ± 4.05<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 10.6 ± 4.3<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 356 ± 127<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 214 ± 129<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 5.4 ± 2.8<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="center" valign="top"> 12-18<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> <br/>14 </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 52 ± 15<br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top"> 34.5 ± 12.2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2.7 ± 1.5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 14.7 ± 8.6<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 466 ± 236<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 136 ± 57<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 4.7 ± 1.9<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>  </paragraph>
                        <paragraph>a: Sirolimus co-administered with cyclosporine oral solution [MODIFIED] (e.g., Neoral<sup>®</sup> Oral Solution) and/or cyclosporine capsules [MODIFIED] (e.g., Neoral<sup>®</sup> Soft Gelatin Capsules).</paragraph>
                        <paragraph>b: As measured by Liquid Chromatographic/Tandem Mass Spectrometric Method (LC/MS/MS)</paragraph>
                        <paragraph>c: Oral-dose clearance adjusted by either body weight (kg) or body surface area (m<sup>2</sup>).</paragraph>
                        <paragraph>Table 7 below summarizes pharmacokinetic data obtained in pediatric dialysis patients with chronically impaired renal function.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 7: SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN ± SD) IN PEDIATRIC PATIENTS WITH END-STAGE KIDNEY DISEASE MAINTAINED ON HEMODIALYSIS OR PERITONEAL DIALYSIS (1, 3, 9, 15 mg/m<sup>2</sup> SINGLE DOSE)*</content>
                        </paragraph>
                        <br/>
                        <paragraph>                       </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="584.4685">
                           <colgroup>
                              <col width="22.5167823415633%"/>
                              <col width="13.5396518375242%"/>
                              <col width="19.4902719308226%"/>
                              <col width="18.580043235863%"/>
                              <col width="25.8732506542269%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Age Group (y)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> <br/>n </td>
                                 <td styleCode="Rrule" valign="top"> tmax (h)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> t<sub>1/2</sub>(h)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> CL/F/WT (mL/h/kg)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> 5-11<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> <br/>9 </td>
                                 <td styleCode="Rrule" valign="top"> 1.1 ± 0.5<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 71 ± 40<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 580 ± 450<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> 12-18<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> <br/>11 </td>
                                 <td styleCode="Rrule" valign="top"> 0.79 ± 0.17<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 55 ± 18<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 450 ± 232<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>  </paragraph>
                        <paragraph>* All subjects received sirolimus oral solution.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Geriatric</content>
                        </paragraph>
                        <paragraph>Clinical studies of sirolimus did not include a sufficient number of patients &gt;65 years of age to determine whether they will respond differently than younger patients. After the administration of sirolimus oral solution or tablets, sirolimus trough concentration data in renal transplant patients &gt;65 years of age were similar to those in the adult population 18 to 65 years of age.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gender</content>
                        </paragraph>
                        <paragraph>Sirolimus clearance in males was 12% lower than that in females; male subjects had a significantly longer t<sub>1/2</sub>than did female subjects (72.3 hours versus 61.3 hours). Dose adjustments based on gender are not recommended.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Race</content>
                        </paragraph>
                        <paragraph>In the phase 3 trials for the prophylaxis of organ rejection following renal transplantation using sirolimus solution or tablets and cyclosporine oral solution [MODIFIED] (e.g., Neoral<sup>®</sup> Oral Solution) and/or cyclosporine capsules [MODIFIED] (e.g., Neoral<sup>®</sup> Soft Gelatin Capsules) [<content styleCode="italics">see Clinical Studies (<linkHtml href="#Section_14">14</linkHtml>)</content>], there were no significant differences in mean trough sirolimus concentrations over time between Black (n = 190) and non-Black (n = 852) patients during the first 6 months after transplantation.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug-Drug Interactions</content>
                        </paragraph>
                        <paragraph>Sirolimus is known to be a substrate for both cytochrome CYP3A4 and P-gp. The pharmacokinetic interaction between sirolimus and concomitantly administered drugs is discussed below. Drug interaction studies have not been conducted with drugs other than those described below.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cyclosporine: </content>Cyclosporine is a substrate and inhibitor of CYP3A4 and P-gp. Sirolimus should be taken 4 hours after administration of cyclosporine oral solution (MODIFIED) and/or cyclosporine capsules (MODIFIED). Sirolimus concentrations may decrease when cyclosporine is discontinued, unless the sirolimus dose is increased [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.2">2.2</linkHtml>), Drug Interactions (<linkHtml href="#Section_7.1">7.1</linkHtml>)</content>].</paragraph>
                        <paragraph>In a single-dose drug-drug interaction study, 24 healthy volunteers were administered 10 mg sirolimus tablets either simultaneously or 4 hours after a 300-mg dose of Neoral<sup>®</sup> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]). For simultaneous administration, mean C<sub>max</sub> and AUC were increased by 512% and 148%, respectively, relative to administration of sirolimus alone. However, when given 4 hours after cyclosporine administration, sirolimus C<sub>max</sub> and AUC were both increased by only 33% compared with administration of sirolimus alone.</paragraph>
                        <paragraph>In a single dose drug-drug interaction study, 24 healthy volunteers were administered 10 mg sirolimus oral solution either simultaneously or 4 hours after a 300 mg dose of Neoral<sup>®</sup> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]). For simultaneous administration, the mean C<sub>max</sub>and  AUC of sirolimus, following simultaneous administration were increased by 116% and 230%, respectively, relative to administration of sirolimus alone. However, when given 4 hours after Neoral<sup>®</sup> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]) administration, sirolimus C<sub>max</sub>and AUC were increased by only 37% and 80%, respectively, compared with administration of sirolimus alone.</paragraph>
                        <paragraph>In a single-dose cross-over drug-drug interaction study, 33 healthy volunteers received 5 mg sirolimus oral solution alone, 2 hours before, and 2 hours after a 300 mg dose of Neoral<sup>®</sup> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]). When given 2 hours before Neoral<sup>®</sup> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]) administration, sirolimus C<sub>max</sub> and AUC were comparable to those with administration of sirolimus alone. However, when given 2 hours after, the mean C<sub>max</sub>and AUC of sirolimus were increased by 126% and 141%, respectively, relative to administration of sirolimus alone.</paragraph>
                        <paragraph>Mean cyclosporine C<sub>max</sub>and AUC were not significantly affected when sirolimus oral solution was given simultaneously or when administered 4 hours after Neoral<sup>®</sup> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]). However, after multiple-dose administration of sirolimus given 4 hours after Neoral<sup>®</sup> in renal post-transplant patients over 6 months, cyclosporine oral-dose clearance was reduced, and lower doses of Neoral<sup>®</sup> Soft Gelatin Capsules (cyclosporine capsules [MODIFIED]) were needed to maintain target cyclosporine concentration.</paragraph>
                        <paragraph>In a multiple-dose study in 150 psoriasis patients, sirolimus 0.5, 1.5, and 3 mg/m2/day was administered simultaneously with Sandimmune<sup>®</sup> Oral Solution (cyclosporine Oral Solution) 1.25 mg/kg/day. The increase in average sirolimus trough concentrations ranged between 67% to 86% relative to when sirolimus was administered without cyclosporine. The intersubject variability (% CV) for sirolimus trough concentrations ranged from 39.7% to 68.7%. There was no significant effect of multiple-dose sirolimus on cyclosporine trough concentrations following Sandimmune<sup>®</sup> Oral Solution (cyclosporine oral solution) administration. However, the % CV was higher (range 85.9% -165%) than those from previous studies. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Diltiazem:</content> Diltiazem is a substrate and inhibitor of CYP3A4 and P-gp; sirolimus concentrations should be monitored and a dose adjustment may be necessary [<content styleCode="italics">see Drug Interactions (<linkHtml href="#Section_7.4">7.4</linkHtml>)</content>]. The simultaneous oral administration of 10 mg of sirolimus oral solution and 120 mg of diltiazem to 18 healthy volunteers significantly affected the bioavailability of sirolimus. Sirolimus C<sub>max</sub>, t<sub>max</sub>, and AUC were increased 1.4-, 1.3-, and 1.6-fold, respectively. Sirolimus did not affect the pharmacokinetics of either diltiazem or its metabolites desacetyldiltiazem and desmethyldiltiazem. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Erythromycin:</content> Erythromycin is a substrate and inhibitor of CYP3A4 and P-gp; co-administration of sirolimus oral solution or tablets and erythromycin is not recommended [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.20">5.20</linkHtml>), Drug Interactions (<linkHtml href="#Section_7.2">7.2</linkHtml>)</content>]. The simultaneous oral administration of 2 mg daily of sirolimus oral solution and 800 mg q 8h of erythromycin as erythromycin ethylsuccinate tablets at steady state to 24 healthy volunteers significantly affected the bioavailability of sirolimus and erythromycin. Sirolimus C<sub>max</sub> and AUC were increased 4.4- and 4.2-fold respectively and t<sub>max</sub> was increased by 0.4 hr. Erythromycin C<sub>max</sub> and AUC were increased 1.6- and 1.7-fold, respectively, and t<sub>max</sub> was increased by 0.3 hr.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Ketoconazole: </content>Ketoconazole is a strong inhibitor of CYP3A4 and P-gp; co-administration of sirolimus oral solution or tablets and ketoconazole is not recommended [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.20">5.20</linkHtml>), Drug Interactions (<linkHtml href="#Section_7.2">7.2</linkHtml>)</content>]. Multiple-dose ketoconazole administration significantly affected the rate and extent of absorption and sirolimus exposure after administration of sirolimus oral solution, as reflected by increases in sirolimus C<sub>max</sub>, t<sub>max</sub>, and AUC of 4.3-fold, 38%, and 10.9-fold, respectively. However, the terminal t½ of sirolimus was not changed. Single-dose sirolimus did not affect steady-state 12-hour plasma ketoconazole concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Rifampin: </content>Rifampin is a strong inducer of CYP3A4 and P-gp; co-administration of sirolimus oral solution or tablets and rifampin is not recommended. In patients where rifampin is indicated, alternative therapeutic agents with less enzyme induction potential should be considered [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.20">5.20</linkHtml>), Drug Interactions (<linkHtml href="#Section_7.2">7.2</linkHtml>)</content>]. Pretreatment of 14 healthy volunteers with multiple doses of rifampin, 600 mg daily for 14 days, followed by a single 20-mg dose of sirolimus oral solution, greatly decreased sirolimus AUC and C<sub>max</sub> by about 82% and 71%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Verapamil: </content>Verapamil is a substrate and inhibitor of CYP3A4 and P-gp; sirolimus concentrations should be monitored and a dose adjustment may be necessary; [<content styleCode="italics">see Drug Interactions (<linkHtml href="#Section_7.4">7.4</linkHtml>)</content>]. The simultaneous oral administration of 2 mg daily of sirolimus oral solution and 180 mg q 12h of verapamil at steady state to 25 healthy volunteers significantly affected the bioavailability of sirolimus and verapamil. Sirolimus C<sub>max</sub> and AUC were increased 2.3- and 2.2-fold, respectively, without substantial change in t<sub>max</sub>. The C<sub>max</sub> and AUC of the pharmacologically active S(-) enantiomer of verapamil were both increased 1.5-fold and t<sub>max</sub> was decreased by 1.2 hr.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Drugs Which May Be Co-administered Without Dose Adjustment</content>
                        </paragraph>
                        <paragraph>Clinically significant pharmacokinetic drug-drug interactions were not observed in studies of drugs listed below. Sirolimus and these drugs may be co-administered without dose adjustments.</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <paragraph>Acyclovir</paragraph>
                           </item>
                           <item>
                              <paragraph>Atorvastatin</paragraph>
                           </item>
                           <item>
                              <paragraph>Digoxin</paragraph>
                           </item>
                           <item>
                              <paragraph>Glyburide</paragraph>
                           </item>
                           <item>
                              <paragraph>Nifedipine</paragraph>
                           </item>
                           <item>
                              <paragraph>Norgestrel/ethinyl     estradiol (Lo/Ovral<sup>®</sup>)</paragraph>
                           </item>
                           <item>
                              <paragraph>Prednisolone</paragraph>
                           </item>
                           <item>
                              <paragraph>Sulfamethoxazole/trimethoprim     (Bactrim<sup>®</sup>)</paragraph>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Other Drug-Drug Interactions</content>
                        </paragraph>
                        <paragraph>Co-administration of sirolimus with other known strong inhibitors of CYP3A4 and/or P-gp (such as voriconazole, itraconazole, telithromycin, or clarithromycin) or other known strong inducers of CYP3A4 and/or P-gp (such as rifabutin) is not recommended [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.20">5.20</linkHtml>), Drug Interactions (<linkHtml href="#Section_7.2">7.2</linkHtml>)</content>]. In patients in whom strong inhibitors or inducers of CYP3A4 are indicated, alternative therapeutic agents with less potential for inhibition or induction of CYP3A4 should be considered.</paragraph>
                        <paragraph>Care should be exercised when drugs or other substances that are substrates and/or inhibitors or inducers of CYP3A4 are administered concomitantly with sirolimus. Other drugs that have the potential to increase sirolimus blood concentrations include (but are not limited to):</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <paragraph>Calcium channel blockers: nicardipine.</paragraph>
                           </item>
                           <item>
                              <paragraph>Antifungal agents: clotrimazole, fluconazole.</paragraph>
                           </item>
                           <item>
                              <paragraph>Antibiotics: troleandomycin.</paragraph>
                           </item>
                           <item>
                              <paragraph>Gastrointestinal prokinetic agents: cisapride, metoclopramide.</paragraph>
                           </item>
                           <item>
                              <paragraph>Other drugs: bromocriptine, cimetidine, danazol, letermovir, <content styleCode="italics">protease inhibitors (e.g., for HIV and     hepatitis C that include drugs such as ritonavir, indinavir, boceprevir, and telaprevir)</content>.</paragraph>
                           </item>
                        </list>
                        <paragraph>Other drugs that have the potential to decrease sirolimus concentrations include (but are not limited to):</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <paragraph>Anticonvulsants: carbamazepine, phenobarbital, phenytoin.</paragraph>
                           </item>
                           <item>
                              <paragraph>Antibiotics: rifapentine.</paragraph>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Other Drug-Food Interactions</content>
                        </paragraph>
                        <paragraph>Grapefruit juice reduces CYP3A4-mediated drug metabolism. Grapefruit juice must not be taken with or used for dilution of sirolimus [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.9">2.9</linkHtml>), Drug Interactions (<linkHtml href="#Section_7.3">7.3</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="italics">Drug-Herb Interactions</content>
                        </paragraph>
                        <paragraph> St. John’s Wort (<content styleCode="italics">Hypericum perforatum</content>) induces CYP3A4 and P-gp. Since sirolimus is a substrate for both cytochrome CYP3A4 and P-gp, there is the potential that the use of St. John’s Wort in patients receiving sirolimus could result in reduced sirolimus concentrations [<content styleCode="italics">see Drug Interactions (<linkHtml href="#Section_7.4">7.4</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="bafd31f5-c915-48a2-88bd-13a0b8444f31"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20231205"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="721839fa-2c28-4c5a-82be-d870ab0165d9"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Carcinogenicity studies were conducted in mice and rats. In an 86-week female mouse study at sirolimus doses 30 to 120 times higher than the 2 mg daily clinical dose (adjusted for body surface area), there was a statistically significant increase in malignant lymphoma at all dose levels compared with controls. In a second mouse study at dosages that were approximately 3 to 16 times the clinical dose (adjusted for body surface area), hepatocellular adenoma and carcinoma in males were considered sirolimus-related. In the 104-week rat study at dosages equal to or lower than the clinical dose of 2 mg daily (adjusted for body surface area), there were no significant findings.</paragraph>
                        <paragraph>Sirolimus was not genotoxic in the <content styleCode="italics">in vitro </content>bacterial reverse mutation assay, the Chinese hamster ovary cell chromosomal aberration assay, the mouse lymphoma cell forward mutation assay, or the <content styleCode="italics">in vivo </content>mouse micronucleus assay.</paragraph>
                        <paragraph>When female rats were treated by oral gavage with sirolimus and mated to untreated males, female fertility was decreased at 0.5 mg/kg (2.5-fold the clinical dose of 2 mg, on a body surface area basis) due to decreased implantation. In addition, reduced ovary and uterus weight were observed. The NOAEL for female rat fertility was 0.1 mg/kg (0.5-fold the clinical dose of 2 mg).</paragraph>
                        <paragraph>When male rats were treated by oral gavage with sirolimus and mated to untreated females, male fertility was decreased at 2 mg/kg (9.7-fold the clinical dose of 2 mg, on a body surface area basis). Atrophy of testes, epididymides, prostate, seminiferous tubules, and reduced sperm counts were observed. The NOAEL for male rat fertility was 0.5 mg/kg (2.5-fold the clinical dose of 2 mg).</paragraph>
                        <paragraph> Testicular tubular degeneration was also seen in a 4-week intravenous study of sirolimus in monkeys at 0.1 mg/kg (1-fold the clinical dose of 2 mg, on a body surface area basis).</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="33bc424b-de92-47f0-b652-e27982127511"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20231205"/>
               <component>
                  <section ID="Section_14.1">
                     <id root="27f1ce31-e714-4dbf-a430-8e0b035f58b2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.1 Prophylaxis of Organ Rejection in Renal Transplant Patients</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Sirolimus</content>
                           </content>
                           <content styleCode="underline">
                              <content styleCode="italics">Oral Solution</content>
                           </content>
                        </paragraph>
                        <paragraph>The safety and efficacy of sirolimus oral solution for the prevention of organ rejection following renal transplantation were assessed in two randomized, double-blind, multicenter, controlled trials. These studies compared two dose levels of sirolimus oral solution (2 mg and 5 mg, once daily) with azathioprine (Study 1) or placebo (Study 2) when administered in combination with cyclosporine and corticosteroids. Study 1 was conducted in the United States at 38 sites. Seven hundred nineteen (719) patients were enrolled in this trial and randomized following transplantation; 284 were randomized to receive sirolimus oral solution 2 mg/day; 274 were randomized to receive sirolimus oral solution 5 mg/day, and 161 to receive azathioprine 2-3 mg/kg/day. Study 2 was conducted in Australia, Canada, Europe, and the United States, at a total of 34 sites. Five hundred seventy-six (576) patients were enrolled in this trial and randomized before transplantation; 227 were randomized to receive sirolimus oral solution 2 mg/day; 219 were randomized to receive sirolimus oral solution 5 mg/day, and 130 to receive placebo. In both studies, the use of antilymphocyte antibody induction therapy was prohibited. In both studies, the primary efficacy endpoint was the rate of efficacy failure in the first 6 months after transplantation. Efficacy failure was defined as the first occurrence of an acute rejection episode (confirmed by biopsy), graft loss, or death.</paragraph>
                        <paragraph>The tables below summarize the results of the primary efficacy analyses from these trials. Sirolimus oral solution, at doses of 2 mg/day and 5 mg/day, significantly reduced the incidence of efficacy failure (statistically significant at the &lt; 0.025 level; nominal significance level adjusted for multiple [2] dose comparisons) at 6 months following transplantation compared with both azathioprine and placebo.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 8: INCIDENCE (%) OF EFFICACY FAILURE AT 6 AND 24 MONTHS FOR STUDY 1<sup>a,b</sup>
                           </content>
                        </paragraph>
                        <paragraph>                                                                                      </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <colgroup>
                              <col width="39.26%"/>
                              <col width="21.66%"/>
                              <col width="19.16%"/>
                              <col width="19.92%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Parameter<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Sirolimus Oral Solution 2 mg/day<br/> (n = 284)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Sirolimus Oral Solution 5 mg/day<br/>  (n =             274)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Azathioprine<br/> 2-3 mg/kg/day<br/> (n = 161)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Efficacy             failure at 6 months<sup>c</sup>
                                    </content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 18.7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 16.8<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 32.3<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="italics">Components             of efficacy failure</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Biopsy-proven<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 16.5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 11.3<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 29.2<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> acute rejection<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Graft loss<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 1.1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2.9<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2.5<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Death<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 1.8<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Lost to             follow-up<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.4<br/> </td>
                                 <td styleCode="Rrule" valign="top">      0.7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.6<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Efficacy             failure at 24 months</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 32.8<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 25.9<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 36.0<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="italics">Components             of efficacy failure</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Biopsy-proven             acute rejection<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 23.6<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 17.5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 32.3<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Graft loss<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 3.9<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 4.7<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 3.1<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Death<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 4.2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 3.3<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> Lost to             follow-up<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 1.1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.4<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 0.6<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <paragraph>a: Patients received cyclosporine and corticosteroids. </paragraph>
                        <paragraph>b: Includes patients who prematurely discontinued treatment. </paragraph>
                        <paragraph>c: Primary endpoint.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 9: INCIDENCE (%) OF EFFICACY FAILURE AT 6 AND 36 MONTHS FOR STUDY 2<sup>a,b</sup>
                           </content>
                        </paragraph>
                        <paragraph>                                                                                      </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <colgroup>
                              <col width="39.12%"/>
                              <col width="26.5%"/>
                              <col width="19.68%"/>
                              <col width="14.7%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus Oral Solution 2 mg/day<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus Oral Solution 5 mg/day<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Placebo <br/>(n = 130)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Parameter<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 227)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 219)<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Efficacy failure at 6             months</content>c<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 30.0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 25.6<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 47.7<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="italics">Components of efficacy failure</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Biopsy-proven acute rejection<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 24.7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 19.2<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 41.5<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Graft loss<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 3.1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 3.7<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 3.9<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Death<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2.2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2.7<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 2.3<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Lost to follow-up<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Efficacy failure at 36 months</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 44.1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 41.6<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 54.6<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="italics">Components of efficacy failure</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Biopsy-proven             acute rejection<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 32.2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 27.4<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 43.9<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Graft loss<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 6.2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 7.3<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 4.6<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Death<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 5.7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 5.9<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 5.4<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> Lost to follow-up<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.9<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 0.8<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>a: Patients received cyclosporine and corticosteroids.</paragraph>
                        <paragraph> b: Includes patients who prematurely discontinued treatment.</paragraph>
                        <paragraph>c: Primary endpoint.</paragraph>
                        <paragraph>Patient and graft survival at 1 year were co-primary endpoints. The following table shows graft and patient survival at 1 and 2 years in Study 1, and 1 and 3 years in Study 2. The graft and patient survival rates were similar in patients treated with sirolimus and comparator-treated patients.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 10: GRAFT AND PATIENT SURVIVAL (%) FOR STUDY 1 (12 AND 24 MONTHS) AND STUDY 2 (12 AND 36 MONTHS)<sup>a,b</sup>
                           </content>
                        </paragraph>
                        <br/>
                        <paragraph>                                                                                                           </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="0">
                           <colgroup>
                              <col width="20%"/>
                              <col width="23.4679802955665%"/>
                              <col width="20.5221674876847%"/>
                              <col width="20.8177339901478%"/>
                              <col width="15.192118226601%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold"> </content>
                                    <br/> <content styleCode="bold"> </content>
                                    <br/> Parameter<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus Oral Solution 2 mg/day<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus Oral Solution 5 mg/day<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Azathioprine 2-3 mg/kg/day<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Placebo<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Study 1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 284)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 274)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 161)<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Graft survival<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 12<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 94.7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 92.7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 93.8<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 24<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 85.2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 89.1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 90.1<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Patient survival<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 12<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 97.2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 96.0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 98.1<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 24<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 92.6<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 94.9<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 96.3<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Study 2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 227)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 219)<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top"> (n = 130)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Graft survival<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 12<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 89.9<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 90.9<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 87.7<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 36<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 81.1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 79.9<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 80.8<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Patient survival<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 12<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 96.5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 95.0<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 94.6<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> Month 36<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 90.3<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 89.5<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 90.8<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>  </paragraph>
                        <paragraph>a: Patients received cyclosporine and corticosteroids.</paragraph>
                        <paragraph>b: Includes patients who prematurely discontinued treatment.</paragraph>
                        <paragraph>The reduction in the incidence of first biopsy-confirmed acute rejection episodes in patients treated with sirolimus compared with the control groups included a reduction in all grades of rejection.</paragraph>
                        <paragraph>In Study 1, which was prospectively stratified by race within center, efficacy failure was similar for sirolimus oral solution 2 mg/day and lower for sirolimus oral solution 5 mg/day compared with azathioprine in Black patients. In Study 2, which was not prospectively stratified by race, efficacy failure was similar for both sirolimus oral solution doses compared with placebo in Black patients. The decision to use the higher dose of sirolimus oral solution in Black patients must be weighed against the increased risk of dose-dependent adverse events that were observed with the sirolimus oral solution 5-mg dose [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 11: PERCENTAGE OF EFFICACY FAILURE BY RACE AT 6 MONTHS</content>
                           <content styleCode="bold">a,b</content>
                        </paragraph>
                        <br/>
                        <paragraph>                          </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="0">
                           <colgroup>
                              <col width="21.3848469643753%"/>
                              <col width="21.9468138484696%"/>
                              <col width="18.785750125439%"/>
                              <col width="20.2508780732564%"/>
                              <col width="17.6317109884596%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" rowspan="2" align="center" valign="top"> Sirolimus Oral Solution 2 mg/day<br/> </td>
                                 <td styleCode="Rrule" rowspan="2" align="center" valign="top"> Sirolimus Oral Solution 5 mg/day<br/> </td>
                                 <td styleCode="Rrule" rowspan="2" valign="top"> Azathioprine 2-3 mg/kg/day<br/> </td>
                                 <td styleCode="Rrule" rowspan="2" valign="top"> Placebo<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Parameter<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Study 1<br/> Black (n = 166)<br/> Non-Black             (n = 553)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> <content styleCode="bold"> </content>
                                    <br/> 34.9 (n = 63)<br/> 14.0 (n = 221)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> <content styleCode="bold"> </content>
                                    <br/> 18.0 (n = 61)<br/> 16.4 (n = 213)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> <content styleCode="bold"> </content>
                                    <br/> 33.3 (n = 42)<br/> 31.9 (n = 119)<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> Study 2<br/> Black (n = 66)<br/> Non-Black             (n = 510)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> <content styleCode="bold"> </content>
                                    <br/> 30.8 (n = 26)<br/> 29.9 (n = 201)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> <content styleCode="bold"> </content>
                                    <br/> 33.7 (n = 27)<br/> 24.5 (n = 192)<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top"> <content styleCode="bold"> </content>
                                    <br/> 38.5 (n = 13)<br/> 48.7 (n = 117)<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>  </paragraph>
                        <paragraph>a: Patients received cyclosporine and corticosteroids.</paragraph>
                        <paragraph>b: Includes patients who prematurely discontinued treatment.</paragraph>
                        <paragraph>Mean glomerular filtration rates (GFR) post-transplant were calculated by using the Nankivell equation at 12 and 24 months for Study 1, and 12 and 36 months for Study 2. Mean GFR was lower in patients treated with cyclosporine and sirolimus oral solution compared with those treated with cyclosporine and the respective azathioprine or placebo control.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 12: OVERALL CALCULATED GLOMERULAR FILTRATION RATES (Mean ± SEM, cc/min) BY NANKIVELL EQUATION POST-TRANSPLANT<sup>a,b</sup>
                           </content>
                        </paragraph>
                        <br/>
                        <paragraph>                                                                                             </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="0">
                           <colgroup>
                              <col width="18.9505218399691%"/>
                              <col width="23.6277541553923%"/>
                              <col width="22.091225357557%"/>
                              <col width="22.6710475454194%"/>
                              <col width="12.6594511016622%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus<br/> </td>
                                 <td styleCode="Rrule" valign="top"> Azathioprine<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Placebo<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Oral Solution<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Oral Solution<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 2-3 mg/kg/day<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Parameter<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 2 mg/day<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 5 mg/day<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Study 1<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="right" valign="top"> Month 12<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 57.4 ±             1.3<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 54.6 ± 1.3<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 64.1 ± 1.6)<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 269)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 248)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> (n = 149)<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="right" valign="top"> Month 24<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 58.4 ±             1.5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 52.6 ± 1.5<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 62.4 ± 1.9<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 221)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 222)<br/> </td>
                                 <td styleCode="Rrule" valign="top"> (n = 132)<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Study 2<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="right" valign="top"> Month 12<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 52.4 ± 1.5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 51.5 ±             1.5<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 58.0 ± 2.1<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 211)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 199)<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 117)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="right" valign="top"> Month 36<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 48.1 ±             1.8<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 46.1 ± 2.0<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 53.4 ± 2.7<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 183)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 177)<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 102)<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>  </paragraph>
                        <paragraph>a: Includes patients who prematurely discontinued treatment.</paragraph>
                        <paragraph>b: Patients who had a graft loss were included in the analysis with GFR set to 0.0.</paragraph>
                        <paragraph>Within each treatment group in Studies 1 and 2, mean GFR at one-year post-transplant was lower in patients who experienced at least one episode of biopsy-proven acute rejection, compared with those who did not.</paragraph>
                        <paragraph>Renal function should be monitored, and appropriate adjustment of the immunosuppressive regimen should be considered in patients with elevated or increasing serum creatinine levels [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.8">5.8</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Sirolimus</content>
                           <content styleCode="underline"> Tablets</content>
                        </paragraph>
                        <paragraph> The safety and efficacy of sirolimus oral solution and sirolimus tablets for the prevention of organ rejection following renal transplantation were demonstrated to be clinically equivalent in a randomized, multicenter, controlled trial [<content styleCode="italics">see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.2">
                     <id root="24c2bf51-8e86-4f19-9665-9645f4a2346e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.2 Cyclosporine Withdrawal Study in Renal Transplant Patients</title>
                     <text>
                        <paragraph>The safety and efficacy of sirolimus as a maintenance regimen were assessed following cyclosporine withdrawal at 3 to 4 months after renal transplantation. Study 3 was a randomized, multicenter, controlled trial conducted at 57 centers in Australia, Canada, and Europe. Five hundred twenty-five (525) patients were enrolled. All patients in this study received the tablet formulation. This study compared patients who were administered sirolimus, cyclosporine, and corticosteroids continuously with patients who received this same standardized therapy for the first 3 months after transplantation (pre-randomization period) followed by the withdrawal of cyclosporine. During cyclosporine withdrawal, the sirolimus dosages were adjusted to achieve targeted sirolimus whole blood trough concentration ranges (16 to 24 ng/mL until month 12, then 12 to 20 ng/mL thereafter, expressed as chromatographic assay values). At 3 months, 430 patients were equally randomized to either continue sirolimus with cyclosporine therapy or to receive sirolimus as a maintenance regimen following cyclosporine withdrawal.</paragraph>
                        <paragraph>Eligibility for randomization included no Banff Grade 3 acute rejection or vascular rejection episode in the 4 weeks before random assignment, serum creatinine ≤4.5 mg/dL, and adequate renal function to support cyclosporine withdrawal (in the opinion of the investigator). The primary efficacy endpoint was graft survival at 12 months after transplantation. Secondary efficacy endpoints were the rate of biopsy-confirmed acute rejection, patient survival, incidence of efficacy failure (defined as the first occurrence of either biopsy-proven acute rejection, graft loss, or death), and treatment failure (defined as the first occurrence of either discontinuation, acute rejection, graft loss, or death).</paragraph>
                        <paragraph>The following table summarizes the resulting graft and patient survival at 12, 24, and 36 months for this trial. At 12, 24, and 36 months, graft and patient survival were similar for both groups.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 13: GRAFT AND PATIENT SURVIVAL (%): STUDY 3<sup>a</sup>
                           </content>
                        </paragraph>
                        <br/>
                        <paragraph>                                                              </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="659.8795">
                           <colgroup>
                              <col width="26.2319862944674%"/>
                              <col width="41.1770633880883%"/>
                              <col width="32.5909503174443%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> with<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Following             Cyclosporine<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Cyclosporine Therapy<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Withdrawal<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Parameter<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 215)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 215)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Graft Survival<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 12b<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 95.3c<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 97.2<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 24<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 91.6<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 94.0<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 36d<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 87.0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 91.6<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Patient Survival<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 12<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 97.2<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 98.1<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 24<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 94.4<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 95.8<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> Month 36d<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 91.6<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 94.0<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>  </paragraph>
                        <paragraph>a: Includes patients who prematurely discontinued treatment. </paragraph>
                        <paragraph>b: Primary efficacy endpoint.</paragraph>
                        <paragraph>c: Survival including loss to follow-up as an event. </paragraph>
                        <paragraph>d: Initial planned duration of the study.</paragraph>
                        <paragraph>The following table summarizes the results of first biopsy-proven acute rejection at 12 and 36 months. There was a significant difference in first biopsy-proven rejection rates between the two groups after randomization and through 12 months. Most of the post-randomization acute rejections occurred in the first 3 months following randomization.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 14: INCIDENCE OF FIRST BIOPSY-PROVEN ACUTE REJECTION (%) BY TREATMENT GROUP AT 36 MONTHS: STUDY 3<sup>a,b</sup>
                           </content>
                        </paragraph>
                        <br/>
                        <paragraph>                                     </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="0">
                           <colgroup>
                              <col width="51.0539795114263%"/>
                              <col width="20.9810874704492%"/>
                              <col width="27.9649330181245%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Period<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus with<br/> Cyclosporine Therapy<br/> (n = 215)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus Following Cyclosporine Withdrawal (n = 215)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Pre-randomizationc<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 9.3<br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top"> 10.2<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Post-randomization             through 12 monthsc<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 4.2<br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top"> 9.8<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Post-randomization             from 12 to 36 months<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 1.4<br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top"> 0.5<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Post-randomization             through 36 months<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 5.6<br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top"> 10.2<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Total at 36 months<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 14.9<br/> </td>
                                 <td styleCode="Rrule" align="right" valign="top"> 20.5<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> <br/>a: Includes patients             who prematurely discontinued treatment. b: All patients received             corticosteroids.<br/> c:             Randomization occurred at 3 months ± 2 weeks.<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>  </paragraph>
                        <paragraph>Patients receiving renal allografts with ≥4 HLA mismatches experienced significantly higher rates of acute rejection following randomization to the cyclosporine withdrawal group, compared with patients who continued cyclosporine (15.3% versus 3.0%). Patients receiving renal allografts with ≤3 HLA mismatches demonstrated similar rates of acute rejection between treatment groups (6.8% versus 7.7%) following randomization.</paragraph>
                        <paragraph>The following table summarizes the mean calculated GFR in Study 3 (cyclosporine withdrawal study).</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 15: CALCULATED GLOMERULAR FILTRATION RATES (mL/min) BY NANKIVELL EQUATION AT 12, 24, AND 36 MONTHS POST-TRANSPLANT: STUDY 3<sup>a,b,c</sup>
                           </content>
                        </paragraph>
                        <br/>
                        <paragraph>                                                         </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="0">
                           <colgroup>
                              <col width="24.8260533436413%"/>
                              <col width="39.1863161963664%"/>
                              <col width="35.9876304599923%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus with<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus Following<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Parameter<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Cyclosporine Therapy<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Cyclosporine             Withdrawal<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 12<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="right" valign="top"> Mean ± SEM<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 53.2 ±             1.5<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 59.3 ± 1.5<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 208)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 203)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 24<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="right" valign="top"> Mean ± SEM<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 48.4 ±             1.7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 58.4 ± 1.6<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 203)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 201)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Month 36<br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" valign="top">  <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="right" valign="top"> Mean ± SEM<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 47.0 ±             1.8<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 58.5 ± 1.9<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 196)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> (n = 199)<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>  </paragraph>
                        <paragraph>a: Includes patients who prematurely discontinued treatment.</paragraph>
                        <paragraph>b: Patients who had a graft loss were included in the analysis and had their GFR set to 0.0. </paragraph>
                        <paragraph>c: All patients received corticosteroids.</paragraph>
                        <paragraph>The mean GFR at 12, 24, and 36 months, calculated by the Nankivell equation, was significantly higher for patients receiving sirolimus as a maintenance regimen following cyclosporine withdrawal than for those in the sirolimus with cyclosporine therapy group. Patients who had an acute rejection prior to randomization had a significantly higher GFR following cyclosporine withdrawal compared to those in the sirolimus with cyclosporine group. There was no significant difference in GFR between groups for patients who experienced acute rejection post-randomization.</paragraph>
                        <paragraph> Although the initial protocol was designed for 36 months, there was a subsequent amendment to extend this study. The results for the cyclosporine withdrawal group at months 48 and 60 were consistent with the results at month 36. Fifty-two percent (112/215) of the patients in the sirolimus with cyclosporine withdrawal group remained on therapy to month 60 and showed sustained GFR.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.3">
                     <id root="be561560-0e7a-432c-addd-b267cc6342ea"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.3 High-Immunologic Risk Renal Transplant Patients</title>
                     <text>
                        <paragraph>Sirolimus was studied in a one-year, clinical trial in high risk patients (Study 4) who were defined as Black transplant recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reasons and/or patients with high panel-reactive antibodies (PRA; peak PRA level &gt;80%). Patients received concentration-controlled sirolimus and cyclosporine (MODIFIED), and corticosteroids per local practice. The sirolimus dose was adjusted to achieve target whole blood trough sirolimus concentrations of 10-15 ng/mL (chromatographic method) throughout the 12-month study period. The cyclosporine dose was adjusted to achieve target whole blood trough concentrations of 200-300 ng/mL through week 2, 150-200 ng/mL from week 2 to week 26, and 100-150 ng/mL from week 26 to week 52 [<content styleCode="italics">see Clinical Pharmacology (12.3)</content>] for the observed trough concentrations ranges. Antibody induction was allowed per protocol as prospectively defined at each transplant center, and was used in 88.4% of patients. The study was conducted at 35 centers in the United States. A total of 224 patients received a transplant and at least one dose of sirolimus and cyclosporine and was comprised of 77.2% Black patients, 24.1% repeat renal transplant recipients, and 13.5% patients with high PRA. Efficacy was assessed with the following endpoints, measured at 12 months: efficacy failure (defined as the first occurrence of biopsy-confirmed acute rejection, graft loss, or death), first occurrence of graft loss or death, and renal function as measured by the calculated GFR using the Nankivell formula. The table below summarizes the result of these endpoints.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 16: EFFICACY FAILURE, GRAFT LOSS OR DEATH AND CALCULATED GLOMERULAR FUNCTION RATES (mL/min) BY NANKIVELL EQUATION AT 12 MONTHS POST-TRANSPLANT: STUDY 4</content>
                        </paragraph>
                        <br/>
                        <paragraph>                  </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="559.7305">
                           <colgroup>
                              <col width="33.2778899845551%"/>
                              <col width="66.7221100154449%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Parameter<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus with             Cyclosporine, Corticosteroids<br/> (n = 224)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Efficacy Failure (%)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 23.2<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Graft             Loss or Death (%)<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top">                                          9.8<br/>  <br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> Renal             Function (mean ± SEM)<sup>a,b</sup>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 52.6 ± 1.6<br/> n = 222)<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>  </paragraph>
                        <br/>
                        <br/>
                        <paragraph>a: Calculated glomerular filtration rate by Nankivell equation.</paragraph>
                        <paragraph>b: Patients who had graft loss were included in this analysis with GFR set to 0.</paragraph>
                        <paragraph> Patient survival at 12 months was 94.6%. The incidence of biopsy-confirmed acute rejection was 17.4% and the majority of the episodes of acute rejection were mild in severity.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.4">
                     <id root="9765a199-320e-4235-89bc-7d473aac45d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.4 Conversion from Calcineurin Inhibitors to Sirolimus in Maintenance Renal Transplant Patients</title>
                     <text>
                        <paragraph>Conversion from calcineurin inhibitors (CNI) to sirolimus was assessed in maintenance renal transplant patients 6 months to 10 years post-transplant (Study 5). This study was a randomized, multicenter, controlled trial conducted at 111 centers globally, including US and Europe, and was intended to show that renal function was improved by conversion from CNI to sirolimus. Eight hundred thirty (830) patients were enrolled and stratified by baseline calculated glomerular filtration rate (GFR, 20-40 mL/min versus greater than 40 mL/min). In this trial there was no benefit associated with conversion with regard to improvement in renal function and a greater incidence of proteinuria in the sirolimus conversion arm. In addition, enrollment of patients with baseline calculated GFR less than 40 mL/min was discontinued due to a higher rate of serious adverse events, including pneumonia, acute rejection, graft loss and death [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#Section_6.4">6.4</linkHtml>)</content>].</paragraph>
                        <paragraph>This study compared renal transplant patients (6-120 months after transplantation) who were converted from calcineurin inhibitors to sirolimus, with patients who continued to receive calcineurin inhibitors. Concomitant immunosuppressive medications included mycophenolate mofetil (MMF), azathioprine (AZA), and corticosteroids. Sirolimus was initiated with a single loading dose of 12-20 mg, after which dosing was adjusted to achieve a target sirolimus whole blood trough concentration of 8-20 ng/mL (chromatographic method). The efficacy endpoint was calculated GFR at 12 months post-randomization. Additional endpoints included biopsy-confirmed acute rejection, graft loss, and death. Findings in the patient stratum with baseline calculated GFR greater than 40 mL/min (sirolimus conversion, n = 497; CNI continuation, n = 246) are summarized below. There was no clinically or statistically significant improvement in Nankivell GFR compared to baseline.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 17: RENAL FUNCTION IN STABLE RENAL TRANSPLANT PATIENTS IN PATIENTS WITH BASELINE GFR &gt;40 mL/min THE SIROLIMUS CONVERSION STUDY (STUDY 5)</content>
                        </paragraph>
                        <br/>
                        <paragraph>                    </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="604.5515">
                           <colgroup>
                              <col width="28.0167198328017%"/>
                              <col width="21.8567814321857%"/>
                              <col width="25.3547464525355%"/>
                              <col width="24.7717522824772%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> Parameter<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Sirolimus conversion<br/> N = 496<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> CNI continuation<br/> N = 245<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> Difference (95% CI)<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> GFR mL/min             (Nankivell) at 1 year<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 59.0<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 57.7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 1.3 (-1.1, 3.7)<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> GFR mL/min             (Nankivell) at 2 year<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 53.7<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 52.1<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 1.6 (-1.4, 4.6)<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>  </paragraph>
                        <paragraph>The rates of acute rejection, graft loss, and death were similar at 1 and 2 years. Treatment-emergent adverse events occurred more frequently during the first 6 months after sirolimus conversion. The rates of pneumonia were significantly higher for the sirolimus conversion group.</paragraph>
                        <paragraph>While the mean and median values for urinary protein to creatinine ratio were similar between treatment groups at baseline, significantly higher mean and median levels of urinary protein excretion were seen in the sirolimus conversion arm at 1 year and at 2 years, as shown in the table below [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.9">5.9</linkHtml>)</content>]. In addition, when compared to patients who continued to receive calcineurin inhibitors, a higher percentage of patients had urinary protein to creatinine ratios &gt;1 at 1 and 2 years after sirolimus conversion.</paragraph>
                        <paragraph>This difference was seen in both patients who had a urinary protein to creatinine ratio ≤1 and those who had a protein to creatinine ratio &gt;1 at baseline. More patients in the sirolimus conversion group developed nephrotic range proteinuria, as defined by a urinary protein to creatinine ratio &gt;3.5 (46/482 [9.5%] versus 9/239 [3.8%]), even when the patients with baseline nephrotic range proteinuria were excluded. The rate of nephrotic range proteinuria was significantly higher in the sirolimus conversion group compared to the calcineurin inhibitor continuation group with baseline urinary protein to creatinine ratio &gt;1 (13/29 versus 1/14), excluding patients with baseline nephrotic range proteinuria.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 18: MEAN AND MEDIAN VALUES FOR URINARY PROTEIN TO CREATININE RATIO (mg/mg) BETWEEN TREATMENT GROUPS AT BASELINE, 1 AND 2 YEARS IN THE STRATUM WITH BASELINE CALCULATED GFR &gt;40 mL/min</content>
                        </paragraph>
                        <br/>
                        <paragraph>                                               </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="655.823">
                           <colgroup>
                              <col width="13.4962482255121%"/>
                              <col width="11.2046238085581%"/>
                              <col width="12.3402960859866%"/>
                              <col width="13.3238693976881%"/>
                              <col width="11.2046238085581%"/>
                              <col width="12.3200162238897%"/>
                              <col width="13.3137294666396%"/>
                              <col width="12.7965929831677%"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" valign="top"> <content styleCode="bold">Study period</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" colspan="3" align="center" valign="top"> <content styleCode="bold">Sirolimus Conversion</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" colspan="4" align="center" valign="top"> <content styleCode="bold">CNI Continuation</content>
                                    <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">  <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> <content styleCode="bold">N</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> <content styleCode="bold">Mean ± SD</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> <content styleCode="bold">Median</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> <content styleCode="bold">N</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" valign="top"> <content styleCode="bold">Mean ± SD</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> <content styleCode="bold">Median</content>
                                    <br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> <content styleCode="bold">p-value</content>
                                    <br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="right" valign="top"> Baseline<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 410<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.35 ± 0.76<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.13<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 207<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 0.28 ± 0.61<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.11<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.381<br/> </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top"> 1 year<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 423<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.88 ± 1.61<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.31<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 203<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 0.37 ± 0.88<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.14<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> &lt;0.001<br/> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top"> 2 years<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 373<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.86 ± 1.48<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.32<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 190<br/> </td>
                                 <td styleCode="Rrule" valign="top"> 0.47 ± 0.98<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> 0.13<br/> </td>
                                 <td styleCode="Rrule" align="center" valign="top"> &lt;0.001<br/> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>  </paragraph>
                        <paragraph>The above information should be taken into account when considering conversion from calcineurin inhibitors to sirolimus in stable renal transplant patients due to the lack of evidence showing that renal function improves following conversion, and the finding of a greater increment in urinary protein excretion, and an increased incidence of treatment-emergent nephrotic range proteinuria following conversion to sirolimus.</paragraph>
                        <paragraph>This was particularly true among patients with existing abnormal urinary protein excretion prior to conversion.</paragraph>
                        <paragraph>In an open-label, randomized, comparative, multicenter study where kidney transplant patients were either converted from tacrolimus to sirolimus 3 to 5 months post-transplant (sirolimus group) or remained on tacrolimus, there was no significant difference in renal function at 2 years post-transplant. Overall, 44/131 (33.6%) discontinued treatment in the sirolimus group versus 12/123 (9.8%) in the tacrolimus group. More patients reported adverse events 130/131 (99.2%) versus 112/123 (91.1%) and more patients reported discontinuations from the treatment due to adverse events 28/131 (21.4%) versus 4/123 (3.3%) in the sirolimus group compared to the tacrolimus group.</paragraph>
                        <paragraph> The incidence of biopsy-confirmed acute rejection was higher for patients in the sirolimus group 11/131 (8.4%) compared to the tacrolimus group 2/123 (1.6%) through 2 years post-transplant. The rate of new-onset diabetes mellitus post-randomization, defined as 30 days or longer of continuous or at least 25 days non-stop (without gap) use of any diabetic treatment after randomization, a fasting glucose ≥126 mg/dL or a non-fasting glucose ≥200 mg/dL, was higher in the sirolimus group 15/82 (18.3%) compared to the tacrolimus group 4/72 (5.6%). A greater incidence of proteinuria, was seen in the sirolimus group 19/131 (14.5%) versus 2/123 (1.6%) in the tacrolimus group.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.5">
                     <id root="254adbb2-8d3a-49b1-81de-38487cfe3b87"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.5 Conversion from a CNI-based Regimen to a Sirolimus-based Regimen in Liver Transplant Patients</title>
                     <text>
                        <paragraph>Conversion from a CNI-based regimen to a sirolimus-based regimen was assessed in stable liver transplant patients 6-144 months post-transplant. The clinical study was a 2:1 randomized, multi-center, controlled trial conducted at 82 centers globally, including the US and Europe, and was intended to show that renal function was improved by conversion from a CNI to sirolimus without adversely impacting efficacy or safety. A total of 607 patients were enrolled.</paragraph>
                        <paragraph> The study failed to demonstrate superiority of conversion to a sirolimus-based regimen compared to continuation of a CNI-based regimen in baseline-adjusted GFR, as estimated by Cockcroft-Gault, at 12 months (62 mL/min in the sirolimus conversion group and 63 mL/min in the CNI continuation group). The study also failed to demonstrate non-inferiority, with respect to the composite endpoint consisting of graft loss and death (including patients with missing survival data) in the sirolimus conversion group compared to the CNI continuation group (6.6% versus 5.6%). The number of deaths in the sirolimus conversion group (15/393, 3.8%) was higher than in the CNI continuation group (3/214, 1.4%), although the difference was not statistically significant. The rates of premature study discontinuation (primarily due to adverse events or lack of efficacy), adverse events overall (infections, specifically), and biopsy-proven acute liver graft rejection at 12 months were all significantly greater in the sirolimus conversion group compared to the CNI continuation group.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.6">
                     <id root="e0f447a0-51c7-4639-b8f3-dfc26248b57b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.6 Pediatric Renal Transplant Patients</title>
                     <text>
                        <paragraph>Sirolimus was evaluated in a 36-month, open-label, randomized, controlled clinical trial at 14 North American centers in pediatric (aged 3 to &lt; 18 years) renal transplant patients considered to be at high-immunologic risk for developing chronic allograft nephropathy, defined as a history of one or more acute allograft rejection episodes and/or the presence of chronic allograft nephropathy on a renal biopsy. Seventy-eight (78) subjects were randomized in a 2:1 ratio to sirolimus (sirolimus target concentrations of 5 to 15 ng/mL, by chromatographic assay, n = 53) in combination with a calcineurin inhibitor and corticosteroids or to continue calcineurin-inhibitor-based immunosuppressive therapy (n = 25). The primary endpoint of the study was efficacy failure as defined by the first occurrence of biopsy-confirmed acute rejection, graft loss, or death, and the trial was designed to show superiority of sirolimus added to a calcineurin-inhibitor-based immunosuppressive regimen compared to a calcineurin-inhibitor-based regimen. The cumulative incidence of efficacy failure up to 36 months was 45.3% in the sirolimus group compared to 44.0% in the control group, and did not demonstrate superiority. There was one death in each group. The use of sirolimus in combination with calcineurin inhibitors and corticosteroids was associated with an increased risk of deterioration of renal function, serum lipid abnormalities (including, but not limited to, increased serum triglycerides and cholesterol), and urinary tract infections [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.8">5.8</linkHtml>)</content>]. This study does not support the addition of sirolimus to calcineurin-inhibitor-based immunosuppressive therapy in this subpopulation of pediatric renal transplant patients.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.7">
                     <id root="b43739d4-ff77-40a3-9b7a-16248dfd0f9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>14.7 Lymphangioleiomyomatosis Patients</title>
                     <text>
                        <paragraph>The safety and efficacy of sirolimus for treatment of lymphangioleiomyomatosis (LAM) were assessed in a randomized, double-blind, multicenter, controlled trial. This study compared sirolimus (dose-adjusted to maintain blood trough concentrations between 5-15 ng/mL) with placebo for a 12-month treatment period, followed by a 12-month observation period. Eighty-nine (89) patients were enrolled; 43 patients were randomized to receive placebo and 46 patients to receive sirolimus. The primary endpoint was the difference between the groups in the rate of change (slope) per month in forced expiratory volume in 1 second (FEV1). During the treatment period, the FEV1 slope was -12±2 mL per month in the placebo group and 1±2 mL per month in the sirolimus group (treatment difference = 13 mL (95% CI: 7, 18). The absolute between-group difference in the mean change in FEV1 during the 12-month treatment period was 153 mL, or approximately 11% of the mean FEV1 at enrollment. Similar improvements were seen for forced vital capacity (FVC). After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group (see Figure 1).</paragraph>
                        <paragraph> <content styleCode="bold">FIGURE 1: CHANGE IN FORCED EXPIRATORY VOLUME IN 1 SECOND (FEV1) DURING THE TREATMENT AND OBSERVATION PHASES OF THE STUDY IN LAM PATIENTS</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM2"/>
                        <br/>
                        <paragraph>The rate of change over 12 months of vascular endothelial growth factor-D (VEGF-D), a lymphangiogenic growth factor which has been shown to be elevated in patients with LAM, was significantly different in the sirolimus-treated group (-88.0 ± 16.6 pg/mL/month) compared to placebo (-2.42 ± 17.2 pg/mL/month) with a treatment difference of -86 pg/mL/month (95% CI: -133, -39). The absolute between-group difference in the mean change in VEGF-D during the 12-month treatment period was -1017.2, or approximately 50% of the mean VEGF-D at enrollment.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>sirolimus-fig-1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="sirolimus-fig-1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_15">
               <id root="5f84fc40-afd6-401c-bba2-7a9c23d5d1a8"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>
                     <content styleCode="italics">Clinical Therapeutics</content>, Volume 22, Supplement B, April 2000 [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#Section_2.5">2.5</linkHtml>)</content>].</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20231205"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="14ebb50f-59a8-4898-9f19-13f9606a7f45"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Since sirolimus oral solution is not absorbed through the skin, there are no special precautions. However, if direct contact of the oral solution occurs with the skin or eyes, wash skin thoroughly with soap and water; rinse eyes with plain water.</paragraph>
                  <paragraph> Do not use sirolimus oral solution after the expiration date. The expiration date refers to the last day of that month.</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20231205"/>
               <component>
                  <section ID="Section_17.1">
                     <id root="bc0060f9-b8b2-49b0-a2c1-9897d645cb85"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>16.1 Sirolimus Oral Solution</title>
                     <text>
                        <paragraph>Sirolimus oral solution, 1 mg/mL is available as a yellow or yellow to brown liquid. Each sirolimus oral solution carton, NDC 72205-099-78, contains one 2 oz (60 mL fill) amber glass bottle of sirolimus (concentration of 1 mg/mL), one oral syringe adapter for fitting into the neck of the bottle, sufficient disposable oral syringes (amber color) and caps for daily dosing, and a carrying case.</paragraph>
                        <paragraph>Sirolimus oral solution bottles should be stored protected from light and refrigerated at 2°C to 8°C (36°F to 46°F). Once the bottle is opened, the contents should be used within one month. If necessary, the patient may store the bottles at room temperatures up to 25°C (77°F) for a short period of time (e.g., not more than 15 days for the bottles).</paragraph>
                        <paragraph>A syringe (amber color) and cap are provided for dosing, and the product may be kept in the syringe for a maximum of 24 hours at room temperatures up to 25°C (77°F) or refrigerated at 2°C to 8°C (36°F to 46°F). The syringe should be discarded after one use. After dilution, the preparation should be used immediately.</paragraph>
                        <paragraph> Sirolimus  oral solution provided in bottles may develop a slight haze when refrigerated. If such a haze occurs, allow the product to stand at room temperature and shake gently until the haze disappears. The presence of this haze does not affect the quality of the product.</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="fc129aef-5b67-40a9-ba16-41751da61032"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise patients, their families, and their caregivers to read the Medication Guide and Instructions for Use for the Oral Solution and assist them in understanding its contents. The complete text of the Medication Guide and Instructions for Use for the Oral Solution are reprinted at the end of the document.</paragraph>
                  <paragraph> See FDA-Approved Medication Guide and Instructions for Use for the Oral Solution.</paragraph>
               </text>
               <effectiveTime value="20231205"/>
               <component>
                  <section ID="Section_16.2">
                     <id root="f220e180-083c-419b-8604-7128e2e5afd0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>17.1 Dosage</title>
                     <text>
                        <paragraph>Patients should be given complete dosage instructions [<content styleCode="italics">see FDA-Approved Medication Guide</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.3">
                     <id root="f9f383bf-039b-4194-8539-cb2948ed8056"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>17.2 Skin Cancer Events</title>
                     <text>
                        <paragraph>Advise patients that exposure to sunlight and ultraviolet (UV) light should be limited by wearing protective clothing and using a broad spectrum sunscreen with a high protection factor because of the increased risk for skin cancer [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.18">5.18</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.4">
                     <id root="c985b82c-e58b-4c33-a0ea-c0df1f042613"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>17.3 Pregnancy and Lactation</title>
                     <text>
                        <paragraph>Advise female patients of reproductive potential to avoid becoming pregnant throughout treatment and for 12 weeks after sirolimus therapy has stopped. Sirolimus can cause fetal harm if taken during pregnancy.</paragraph>
                        <paragraph> Advise a pregnant woman of the potential risk to her fetus. Before making a decision to breastfeed, inform the patient that the effects of breastfeeding in infants while taking this drug are unknown, but there is potential for serious adverse effects [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.15">5.15</linkHtml>), Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#Section_8.6">8.2</linkHtml>, <linkHtml href="#Section_8.7">8.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_16.5">
                     <id root="f702b7b0-f352-45c0-bc7a-87db3295f8e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>17.4 Infertility</title>
                     <text>
                        <paragraph>Inform male and female patients that sirolimus may impair fertility [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#Section_5.16">5.16</linkHtml>), Adverse Reactions (<linkHtml href="#Section_6.7">6.7</linkHtml>), Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>, <linkHtml href="#Section_8.7">8.3</linkHtml>), Nonclinical Toxicology (<linkHtml href="#Section_13.1">13.1</linkHtml>)</content>].</paragraph>
                        <paragraph>This product’s label may have been updated. For current Full Prescribing Information, please visit  www.novadozpharma.com.</paragraph>
                        <paragraph>For medical information about sirolimus oral solution, please visit www.novadozpharma.com or call 1-855-668-2369.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Dispense with Medication Guide available at: www.NovadozPharma.com/Products</content>
                        </paragraph>
                        <br/>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Manufactured by:</content> </paragraph>
                        <paragraph>
                           <content styleCode="bold">MSN Pharmaceuticals Inc.</content>
                        </paragraph>
                        <paragraph>Piscataway, NJ 08854</paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Distributed by:</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Novadoz Pharmaceuticals LLC</content>
                        </paragraph>
                        <paragraph> Piscataway, NJ 08854 -3714</paragraph>
                        <br/>
                        <paragraph>Issued: 12/2023</paragraph>
                     </text>
                     <effectiveTime value="20231205"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_61">
               <id root="842289d7-33f5-44bc-b1b6-9abed06ee0b2"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>MEDICATION GUIDE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Dispense with Medication Guide available at: www.NovadozPharma.com/Products<br/>
                     </content>
                  </paragraph>
                  <table cellspacing="0" cellpadding="0" border="0">
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="center" valign="middle">
                              <br/>
                              <content styleCode="bold">MEDICATION GUIDE</content>
                              <br/>Sirolimus  (sir oh' li mus) Oral Solution</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="middle"> <content styleCode="bold">What is             the most important information I should know about sirolimus oral solution?</content>
                              <br/> Sirolimus oral solution can cause             serious side effects, including:<br/> <content styleCode="bold">1.             Increased risk of getting infections. </content>Serious infections             can happen including infections caused by viruses, bacteria, and fungi (yeast). Your doctor may put you on             medicine to help prevent some of these infections.<br/> Call your doctor right away if you             have symptoms of infection including fever or chills while taking sirolimus oral solution.<br/> <content styleCode="bold">2.             Increased risk of getting certain cancers. </content>People who take sirolimus oral solution have a             higher risk of getting lymphoma, and             other cancers, especially skin cancer. Talk with your doctor about your risk for cancer.<br/> <content styleCode="bold">Sirolimus             oral solution has not been shown to be safe and effective in people who have             had liver or lung transplants. Serious complications and death may happen in             people who take sirolimus oral solution after a liver or lung transplant. </content>You should             not take sirolimus oral solution if you have had a liver or lung transplant             without talking with your doctor.<br/> <content styleCode="bold">See             the section “What are the possible side effects of sirolimus oral solution?”             for information about other side effects of sirolimus oral solution.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="middle"> <content styleCode="bold">What is             sirolimus oral solution?</content>
                              <br/> Sirolimus oral solution is a             prescription medicine used to prevent rejection (anti-rejection medicine) in             people 13 years of age and older who have received a kidney transplant.             Rejection is when your body’s immune system recognizes the new organ as a             “foreign” threat and attacks it.<br/> Sirolimus oral solution is used             with other medicines called cyclosporine (Gengraf, Neoral, Sandimmune), and             corticosteroids. Your doctor will decide:<br/> <list listType="unordered" styleCode="disc">
                                 <item>if sirolimus oral solution is right for                 you, and<br/>
                                 </item>
                                 <item>how to best use it with cyclosporine and                 corticosteroids after your transplant.                 <br/>It is                 not known if sirolimus oral solution is safe and effective in children under 13                 years of age.<br/>
                                 </item>
                              </list> Sirolimus oral solution is a prescription             medicine also used to treat lymphangioleiomyomatosis (LAM). LAM is a rare             progressive lung disease that affects predominantly women of childbearing age.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="middle"> <content styleCode="bold">Who should not             take sirolimus oral solution?</content>
                              <br/> Do not take sirolimus oral solution if you are             allergic to sirolimus or any of the other ingredients in sirolimus oral             solution. See the end of this leaflet for a complete list of ingredients in sirolimus             oral solution.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="middle"> <content styleCode="bold">What             should I tell my doctor before taking sirolimus oral solution?</content>
                              <br/> <list listType="unordered" styleCode="disc">
                                 <item>have liver problems<br/>
                                 </item>
                                 <item>have skin cancer or it runs in your family<br/>
                                 </item>
                                 <item>have high cholesterol or triglycerides                 (fat in your blood)<br/>
                                 </item>
                                 <item>are pregnant or are a female who can                 become pregnant. sirolimus oral solution can harm your unborn baby. You should                 not become pregnant during treatment with sirolimus oral solution and for 12                 weeks after ending treatment with sirolimus oral solution. In order to avoid                 pregnancy, a female who can get pregnant should use effective birth control during treatment and for 12 weeks after                 your final dose of sirolimus oral solution. Talk with your doctor about what                 birth control method is right for you during this time. Tell your doctor right                 away if you become pregnant or think you are pregnant during treatment with sirolimus                 oral solution or within 12 weeks after your final dose of sirolimus oral solution.<br/>
                                 </item>
                              </list> <list listType="unordered" styleCode="disc">
                                 <item>It is not known whether sirolimus passes into breast milk; however, there is a risk of serious side                 effects in breastfed infants. You                 and your doctor should decide about the best way to feed your baby if you take sirolimus                 oral solution.<br/>
                                    <content styleCode="bold">Tell your doctor about all the medicines                 you take, </content>including                 prescription and over-the-counter medicines, vitamins and herbal supplements. Using                 sirolimus oral solution with certain medicines may affect each other causing                 serious side effects.<br/>Sirolimus oral solution may affect                 the way other medicines work, and other medicines may affect how sirolimus oral                 solution works. Especially tell your doctor if you take:<br/>
                                 </item>
                              </list> <list listType="unordered" styleCode="disc">
                                 <item>a medicine to lower your cholesterol or triglycerides<br/>
                                 </item>
                                 <item>cyclosporine (including Gengraf, Neoral, Sandimmune) or tacrolimus (Prograf) or other medicines that suppress                 the immune system<br/>
                                 </item>
                                 <item>an antibiotic<br/>
                                 </item>
                                 <item>an antifungal medicine<br/>
                                 </item>
                                 <item>a medicine for high blood pressure or                 heart problems<br/>
                                 </item>
                                 <item>an anti-seizure medicine<br/>
                                 </item>
                                 <item>medicines used to treat stomach acid,                 ulcers, or other gastrointestinal problems<br/>
                                 </item>
                                 <item>bromocriptine mesylate (Parlodel, Cycloset)<br/>
                                 </item>
                                 <item>danazol<br/>
                                 </item>
                                 <item>letermovir (Prevymis)<br/>
                                 </item>
                                 <item>medicines to treat HIV or hepatitis C<br/>
                                 </item>
                                 <item>St. John’s Wort<br/>
                                 </item>
                                 <item>cannabidiol (Epidiolex)<br/>
                                 </item>
                              </list> </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="middle"> <content styleCode="bold">How should I take sirolimus oral solution?</content>
                              <br/> <list listType="unordered" styleCode="disc">
                                 <item>Read the Instructions for Use that comes                 with your sirolimus oral solution for information about the right way to take sirolimus oral solution.<br/>
                                 </item>
                                 <item>Take sirolimus oral solution exactly as                 your doctor tells you to take it.<br/>
                                 </item>
                                 <item>Your doctor will tell you how much sirolimus                 oral solution to take and when to take it. Do not change your dose of sirolimus                 oral solution unless your doctor tells you to.<br/>
                                 </item>
                                 <item>If you                 also take cyclosporine (Gengraf, Neoral, Sandimmune), you should take                 your sirolimus oral solution and cyclosporine about 4 hours apart.<br/>
                                 </item>
                                 <item>Do not stop taking sirolimus oral solution                 or your other anti-rejection medicines unless your doctor tells you to.<br/>
                                 </item>
                                 <item>Your doctor will check the levels of sirolimus                 oral solution in your blood. Your doctor may change your dose of sirolimus oral                 solution depending on your blood test results.<br/>
                                 </item>
                                 <item>sirolimus oral solution is taken by mouth                 1 time each day.<br/>
                                 </item>
                                 <item>Take each dose of sirolimus oral solution the                 same way, either with or without food. Food can affect the amount of medicine                 that gets into your bloodstream. Taking each dose of sirolimus oral solution the                 same way helps keep your blood                 levels of sirolimus oral solution more stable. Do not take sirolimus oral                 solution with grapefruit juice.<br/>
                                 </item>
                                 <item>sirolimus oral solution can develop a                 slight haze when it is refrigerated. If this happens, bring the sirolimus oral solution to room                 temperature and then gently shake the bottle until the haze goes away.<br/>
                                 </item>
                                 <item>If you                 get sirolimus oral solution on your skin, wash the area with soap and water.<br/>
                                 </item>
                                 <item>If you                 get sirolimus oral solution in your eyes, rinse your eyes with water.<br/>
                                 </item>
                                 <item>If you have taken more medicine than you were told, contact a doctor or go to the nearest hospital emergency department right away.<br/>
                                 </item>
                              </list> </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="middle"> <content styleCode="bold">What should I avoid while taking sirolimus             oral solution?</content>
                              <br/> <list listType="unordered" styleCode="disc">
                                 <item>Avoid receiving live vaccines while taking sirolimus oral                 solution. Some vaccines may not work as well while you are taking sirolimus oral solution.<br/>
                                 </item>
                                 <item>Limit your time in sunlight and UV light. Cover your skin with clothing and use a broad spectrum sunscreen with a high protection factor because of the increased risk for skin cancer with sirolimus oral solution.<br/>
                                 </item>
                              </list> </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="middle"> <content styleCode="bold">What             are the possible side effects of sirolimus oral solution? </content>
                              <br/> <content styleCode="bold">Sirolimus             oral solution may cause serious side effects, including:</content>
                              <br/> <list listType="unordered" styleCode="disc">
                                 <item>See <content styleCode="bold">“What is the most important information I                 should know about sirolimus oral                 solution?”</content>
                                    <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">
                                       <content styleCode="bold">Serious allergic reactions. </content> </content>Tell your doctor or get medical help right away if you get any of following symptoms of an allergic reaction:<br/>
                                 </item>
                                 <item>swelling                 of your face, eyes, or mouth<br/>
                                 </item>
                                 <item>chest                 pain or tightness<br/>
                                 </item>
                                 <item>trouble                 breathing or wheezing<br/>
                                 </item>
                                 <item>feeling                 dizzy or faint<br/>
                                 </item>
                                 <item>throat tightness<br/>
                                 </item>
                                 <item>rash                 or peeling of your skin<br/>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Swelling                 (edema). </content>Fluid                 may collect in your hands and feet and in various tissues of your body,                 including in the sac around your                 heart or lungs. Call your doctor if you have trouble breathing.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Poor                 wound healing. </content>sirolimus oral solution may cause your wounds to heal                 slowly or not heal well. Tell your doctor if you have any redness or drainage, your wound does not heal, or the wound                 opens up.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increased                 levels of cholesterol and triglycerides (lipids or fat) in your blood. </content>Your                 doctor should do blood tests to check your lipids during treatment with sirolimus                 oral solution. Your doctor may prescribe treatment with diet, exercise, or                 medicine if your lipid levels are too high. During treatment with sirolimus                 oral solution, your blood levels of cholesterol and triglycerides may remain                 high even if you follow your prescribed treatment plan.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Effects                 on kidney function. </content>When sirolimus oral solution is taken with                 cyclosporine (Gengraf, Neoral, Sandimmune), the function of your transplanted kidney may be affected. Your doctor                 should regularly do tests to check your kidney function while you are taking sirolimus                 oral solution with cyclosporine (Gengraf, Neoral, Sandimmune).<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increased                 protein in your urine. </content>Your doctor may regularly test your urine protein.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increased risk for viral infections.</content>
                                    <br/>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="disc">
                                 <item>Certain viruses can live in your body and                 cause active infections when your immune system is weak. BK virus can affect how your kidney works and cause your                 transplanted kidney to fail.<br/>
                                 </item>
                                 <item>A certain virus can cause a rare serious                 brain infection called Progressive Multifocal Leukoencephalopathy (PML). PML                 usually causes death or severe disability. Call your doctor right away if you notice any new or worsening                 medical problems such as:<br/>
                                    <list listType="unordered" styleCode="Square">
                                       <item>confusion<br/>
                                       </item>
                                       <item>sudden change in thinking, walking,                     strength on one side of your body<br/>
                                       </item>
                                       <item>other problems that have lasted over                     several days<br/>
                                       </item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Lung or                 breathing problems. </content>This can sometimes lead to death. Tell                 your doctor if you have a new or worsening                 cough, shortness of breath, difficulty breathing or any new breathing problems.                 Your doctor may need to stop sirolimus oral solution or lower your dose.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Blood                 clotting problems. </content>When sirolimus oral solution is taken with                 cyclosporine or tacrolimus, you may develop a blood clotting problem. Tell your                 doctor if you get any unexplained bleeding or bruising.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Possible                 harm to your unborn baby. </content>sirolimus oral solution can harm your                 unborn baby. You should not become pregnant during treatment with sirolimus                 oral solution and for 12 weeks after ending treatment with sirolimus oral                 solution. See <content styleCode="bold">“What should I tell my                 doctor before taking sirolimus oral                 solution?”.</content>
                                    <br/>
                                 </item>
                              </list> <content styleCode="bold">The             most common side effects of sirolimus oral solution in people with renal             transplant include:</content> <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>high blood pressure      <br/>
                                 </item>
                                 <item>urinary tract infection<br/>
                                 </item>
                                 <item>pain (including stomach and                 joint pain)  <br/>
                                 </item>
                                 <item>low red blood cell count                 (anemia)<br/>
                                 </item>
                                 <item>diarrhea           <br/>
                                 </item>
                                 <item>nausea<br/>
                                 </item>
                                 <item>headache          <br/>
                                 </item>
                                 <item>low platelet count (cells that                 help blood to clot)<br/>
                                 </item>
                                 <item>fever<br/>
                                 </item>
                                 <item>high blood sugar (diabetes)    <br/>
                                 </item>
                              </list>
                              <content styleCode="bold">The most common side effects of sirolimus oral             solution in people with LAM include:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>mouth sores      <br/>
                                 </item>
                                 <item>chest pain<br/>
                                 </item>
                                 <item>diarrhea           <br/>
                                 </item>
                                 <item>upper respiratory tract                 infection<br/>
                                 </item>
                                 <item>stomach pain    <br/>
                                 </item>
                                 <item>headache<br/>
                                 </item>
                                 <item>nausea <br/>
                                 </item>
                                 <item>dizziness<br/>
                                 </item>
                                 <item>sore throat        <br/>
                                 </item>
                                 <item>sore muscles<br/>
                                 </item>
                                 <item>acne<br/>
                                 </item>
                              </list>
                              <content styleCode="bold">Other             side effects that may occur with sirolimus oral solution:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>Sirolimus oral                 solution may affect fertility in females and may affect your ability to become pregnant. Talk to your healthcare                 provider if this is a concern for you.<br/>
                                 </item>
                                 <item>Sirolimus oral                 solution may affect fertility in males and may affect your ability to father a                 child. Talk to your healthcare                 provider if this is a concern for you.<br/>Tell your                 doctor if you have any side effect that bothers you or that does not go away.<br/>These are                 not all of the possible side effects of sirolimus oral solution. For more                 information ask your doctor or pharmacist.<br/>
                                 </item>
                              </list> <content styleCode="bold">Call             your doctor for medical advice about side effects. You may report side effects             to FDA at 1-800-FDA-1088.</content> <br/> </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="middle"> <content styleCode="bold">How             should I store sirolimus oral solution?</content>
                              <br/> <content styleCode="bold">Sirolimus             oral solution:</content>
                              <br/> <list listType="unordered" styleCode="disc">
                                 <item>Store bottles of                 sirolimus oral solution in the refrigerator between 36°F to 46°F (2°C to 8°C).<br/>
                                 </item>
                                 <item>Protect from light.<br/>
                                 </item>
                                 <item>If necessary, bottles of sirolimus oral solution can be stored at room temperature up to 77°F (25°C) for up to 15 days.<br/>
                                 </item>
                                 <item>When a bottle of                 sirolimus oral solution is opened, it should be used within 1 month.<br/>
                                 </item>
                                 <item>Use any diluted sirolimus                 oral solution right away.                   <br/>
                                 </item>
                              </list> Do not use sirolimus oral solution after the expiration date. The expiration date refers to the last day of that month. <br/>Safely throw away medicine that is out of date or no longer needed.<br/>
                              <content styleCode="bold">Keep sirolimus oral solution and all medicines out of             the reach of children.</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="justify" valign="middle"> <content styleCode="bold">General             Information about the safe and effective use of sirolimus oral solution.</content>
                              <br/> Medicines are             sometimes prescribed for purposes other than those listed in a Medication             Guide. Do not use sirolimus oral solution for a condition for which it was not             prescribed. Do not give sirolimus oral solution to other people even if they             have the same symptoms that you have. It may harm them.<br/> This Medication Guide summarizes             the most important information about sirolimus oral solution. If you would like             more information talk to your doctor. You can ask your pharmacist or doctor for             information about sirolimus oral solution that is written for health             professionals.<br/> For more information, go to www.novadozpharma.com             or call 1-855-668-2369.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" align="justify" valign="middle"> <content styleCode="bold">What             are the ingredients in sirolimus oral solution?</content>
                              <br/> Active ingredients: sirolimus<br/> Inactive ingredients: sirolimus oral             solution: Phosal 50 PG<sup>®</sup> (phosphatidylcholine, propylene glycol, sunflower             seed oil glyceride, ethanol, soy fatty acids, ascorbyl palmitate and tocopherol) and             polysorbate 80. sirolimus oral solution contains 1.5%- 2.5% ethanol.<br/> <content styleCode="bold">Manufactured             by:</content>
                              <br/> <content styleCode="bold">MSN Pharmaceuticals             Inc.</content>
                              <br/> Piscataway,             NJ 08854<br/> <content styleCode="bold">Distributed             by:</content>
                              <br/> <content styleCode="bold">Novadoz             Pharmaceuticals LLC</content>
                              <br/> Piscataway, NJ 08854 -3714<br/> The brands listed are trademarks or registered             trademarks of their respective owners and are not affiliated with and do not             endorse Novadoz             Pharmaceuticals LLC.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.                            Revised: December 2023</paragraph>
               </text>
               <effectiveTime value="20231205"/>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_62">
               <id root="b3ce9615-06c6-4519-b116-07b5d9be3f08"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>INSTRUCTIONS FOR USE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Sirolimus (sir oh' li mus) Oral Solution </content>
                  </paragraph>
                  <paragraph>Be sure that you read and understand the following instructions for the correct way to dilute and take Sirolimus oral solution. Ask your pharmacist or doctor if you are not sure.</paragraph>
                  <paragraph>Important:</paragraph>
                  <paragraph>  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <paragraph>Always keep the bottle in an     upright position.</paragraph>
                     </item>
                     <item>
                        <paragraph>You may store sirolimus oral     solution that is in a syringe at room temperature up to 77°F (25°C) or in the     refrigerator at 36°F to 46°F (2°C to 8°C) for up to 24 hours. See “How should I     store sirolimus oral solution?” at the end of this Instructions for Use.</paragraph>
                     </item>
                     <item>
                        <paragraph>Sirolimus oral solution can     develop a slight haze when it is refrigerated. If this happens, bring the     sirolimus oral solution to room temperature and then gently shake the bottle     until the haze goes away.</paragraph>
                     </item>
                     <item>
                        <paragraph>Only use a glass or plastic cup     to dilute sirolimus oral solution.</paragraph>
                     </item>
                     <item>
                        <paragraph>If you are a caregiver, do not     let sirolimus oral solution come in contact with your skin or eyes. If you get     the oral solution on your skin, wash the area well with soap and water. If you get     the oral solution in your eyes, rinse with plain water.</paragraph>
                     </item>
                     <item>
                        <paragraph>If you spill sirolimus oral solution, dry the area with a dry paper towel and then wipe the area with a wet paper towel. Throw away the paper towels in the trash and wash your hands well with soap and water.</paragraph>
                     </item>
                  </list>
                  <paragraph>   </paragraph>
                  <br/>
                  <table cellspacing="0" cellpadding="0" border="0">
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">Each sirolimus oral             solution carton contains:<br/>
                              <renderMultiMedia referencedObject="MM3"/>              You will also need:<br/>             • glass or plastic cup<br/>             • 6 oz. of water or orange juice only<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">             a) a 2 oz. (60 mL fill) amber             glass bottle of sirolimus (concentration of 1 mg/mL)<br/>b) 1 oral syringe adapter for             fitting into the neck of the bottle<br/>c) enough disposable oral syringes (amber color) and caps for daily dosing<br/>d) 1 carrying case <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">Figure             1: Opening the bottle<br/> <br/>
                              <renderMultiMedia referencedObject="MM4"/>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">1. Open the solution bottle.<br/>• Remove the safety cap by pushing down on the cap and at the same time; turn the cap counter clockwise (Figure 1).<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">Figure             2: Inserting adapter<br/>
                              <renderMultiMedia referencedObject="MM5"/>             </td>
                           <td styleCode="Rrule" valign="middle">2. The <content styleCode="bold">first time </content>you use a bottle of sirolimus oral solution:<br/>• Insert the oral syringe adapter (plastic tube with stopper) tightly into the bottle until it is even with the top of the bottle (Figure 2).<br/>             • Do not remove the oral syringe adapter from the bottle once inserted.<br/>              </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">Figure             3: Inserting syringe<br/>
                              <renderMultiMedia referencedObject="MM6"/>      <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">3. Use a new disposable amber oral syringe for each dose of sirolimus oral solution.<br/>• Fully push down (depress) on the plunger of the disposable amber oral syringe.<br/>             • Then, tightly insert the oral syringe into the opening in the adapter (Figure 3).<br/>              </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">Figure             4: Withdrawing solution<br/>
                              <renderMultiMedia referencedObject="MM7"/>                       <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">4. Withdraw the prescribed amount of sirolimus oral solution:<br/>             • Gently pull back the plunger of the syringe until the level of the oral solution is even with the marking on the syringe for your prescribed dose.<br/>             • Always keep the bottle in an upright position.<br/>             • If bubbles form within the oral solution in the syringe, empty the syringe into the bottle and repeat step 4 (Figure 4).<br/>             • You may need to repeat step 4 more than once to draw up your prescribed dose.<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">Figure             5: Capping syringe<br/>
                              <renderMultiMedia referencedObject="MM8"/>                       <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">5. If your doctor tells you to carry your medicine with you:<br/>             • Each dose of sirolimus oral solution should be placed in an oral syringe. Place a cap securely on each syringe. The cap should snap into place (Figure 5).<br/>             • Place the capped syringe in the enclosed carrying case (Figure 6). If you need more than 1 carrying case, talk with your doctor or pharmacist.<br/>             • See ‘How should I store sirolimus oral solution’ for storage instructions. </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">Figure 6: Placing syringe in carrying case<br/>              <renderMultiMedia referencedObject="MM9"/>                      <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">6. Taking a dose of sirolimus oral solution:<br/>             • Choose a clean flat work surface. Place a clean paper towel on the work surface. Wash and dry your hands.<br/>             • Empty the syringe into a glass or plastic cup containing at least 2 ounces (1/4 cup, 60 mL) of water or orange juice, stir vigorously for 1 minute and drink right away (Figure 7).<br/>             • If more than 1 syringe is needed for your prescribed dose, empty the oral solution from each syringe into the same glass or plastic cup of water or orange juice.<br/>             • Refill the container with at least 4 ounces (1/2 cup, 120 mL) of water or orange juice, stir vigorously again and drink the rinse solution. Do not mix sirolimus oral solution with apple juice, grapefruit juice, or other liquids. Only glass or plastic cups should be used to mix sirolimus oral solution.<br/>             • The syringe and cap should be used only one time and then thrown away.<br/>             • Throw away the paper towel and clean the work surface. Wash your hands.<br/>              </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="middle">Figure             7: Emptying syringe into glass<br/>
                              <renderMultiMedia referencedObject="MM10"/>                       <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">7. Always store the bottles of medication in the refrigerator. </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">How should I store sirolimus oral solution?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <paragraph>Store     bottles of sirolimus oral solution in the refrigerator at 36°F to 46°F (2°C to     8°C).</paragraph>
                     </item>
                     <item>
                        <paragraph>Protect     from light.</paragraph>
                     </item>
                     <item>
                        <paragraph>Store sirolimus     oral solution that is in a syringe at room temperature up to 77°F (25°C) or in     the refrigerator at 36°F to 46°F (2°C to 8°C) for up to 24 hours.</paragraph>
                     </item>
                     <item>
                        <paragraph>If     necessary, bottles of sirolimus oral solution can be stored at room temperature     up to 77°F (25°C) for up to 15 days.</paragraph>
                     </item>
                     <item>
                        <paragraph>When a     bottle of sirolimus oral solution is opened, it should be used within 1 month.</paragraph>
                     </item>
                     <item>
                        <paragraph>Use     any diluted sirolimus oral solution right away.</paragraph>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep sirolimus oral solution and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MSN Pharmaceuticals Inc.</content>
                  </paragraph>
                  <paragraph>Piscataway, NJ 08854</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Novadoz Pharmaceuticals LLC</content>
                  </paragraph>
                  <paragraph>Piscataway, NJ 08854 -3714</paragraph>
                  <paragraph>
                     <content styleCode="bold">Issued on: </content>12/2023</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20231205"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>sirolimus-instruction-fig</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sirolimus-instruction-fig.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>sirolimus-instruction-fig-1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sirolimus-instruction-fig-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>sirolimus-instruction-fig-2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sirolimus-instruction-fig-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>sirolimus-instruction-fig-3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sirolimus-instruction-fig-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>sirolimus-instruction-fig-4</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sirolimus-instruction-fig-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>sirolimus-instruction-fig-5</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sirolimus-instruction-fig-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>sirolimus-instructions-fig-6</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sirolimus-instruction-fig-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>sirolimus-instruction-fig-7</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sirolimus-instruction-fig-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="b19a1f91-3397-42e4-90a9-7a2b53c677ce"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Sirolinus Oral Solution 1 mg/mL Container Label</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM11"/>
                  </paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Sirolinus Oral Solution 1 mg/mL Carton Label</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM12"/>
                  </paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">
                           <content styleCode="bold">Sirolinus Oral Solution 1 mg/mL Kit Carton Label</content>
                        </content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM13"/>
                           </content>
                        </content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20231205"/>
               <component>
                  <observationMedia ID="MM11">
                     <text>sirolimus-container-label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sirolimus-container-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>sirolimus-carton-label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sirolimus-carton-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM13">
                     <text>sirolimus-kit-carton-label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="sirolimus-kit-carton-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>